[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 867
6. Philippar U, Roussos ET, Oser M, Yamaguchi H, Kim HD, Giampieri S, Wang Y, Goswami S, Wyckoff JB, Lauffenburger DA, Sahai E, Condeelis JS, Gertler FB: A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell; 2008 Dec;15(6):813-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The spread of cancer during metastatic disease requires that tumor cells subvert normal regulatory networks governing cell motility to invade surrounding tissues and migrate toward blood and lymphatic vessels.
  • Here we show that Mena and Mena(INV) promote carcinoma cell motility and invasiveness in vivo and in vitro, and increase lung metastasis.
  • Mena and Mena(INV) potentiate epidermal growth factor (EGF)-induced membrane protrusion and increase the matrix degradation activity of tumor cells.
  • Upregulation of Mena(INV) could therefore enable tumor cells to invade in response to otherwise benign EGF stimulus levels.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2004 Aug;5(8):647-57 [15366708.001]
  • [Cites] Clin Exp Metastasis. 2009;26(2):153-9 [18985426.001]
  • [Cites] J Natl Cancer Inst. 1982 Mar;68(3):507-17 [6950180.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14509-17 [8182057.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):61-72 [8521618.001]
  • [Cites] Cell. 1996 Oct 18;87(2):227-39 [8861907.001]
  • [Cites] J Cell Sci. 1998 Jan;111 ( Pt 2):199-211 [9405304.001]
  • [Cites] FEBS Lett. 1999 May 14;451(1):68-74 [10356985.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23549-57 [10438535.001]
  • [Cites] Exp Cell Res. 1999 Aug 25;251(1):234-43 [10438589.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] J Cell Biol. 2005 Jan 31;168(3):441-52 [15684033.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5278-83 [15958574.001]
  • [Cites] BMC Biotechnol. 2005;5:14 [15910685.001]
  • [Cites] J Biol Chem. 2005 Aug 5;280(31):28653-62 [15939738.001]
  • [Cites] Cell. 2006 Jan 27;124(2):263-6 [16439202.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1470-8 [16533770.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):213-8 [16546563.001]
  • [Cites] Bioessays. 2006 Apr;28(4):378-86 [16547952.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):395-404 [16651380.001]
  • [Cites] Curr Biol. 2006 Nov 21;16(22):2193-205 [17113383.001]
  • [Cites] Trends Cell Biol. 2007 Mar;17(3):107-17 [17275303.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2649-56 [17363585.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2657-65 [17363586.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3505-11 [17440055.001]
  • [Cites] Development. 2007 Jun;134(11):2027-39 [17507404.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2579-91 [17475772.001]
  • [Cites] EMBO J. 2007 Oct 31;26(21):4597-606 [17914456.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2504-11 [10811132.001]
  • [Cites] Cell. 2000 Jun 23;101(7):717-28 [10892743.001]
  • [Cites] Cancer Res. 2000 Oct 1;60(19):5401-4 [11034079.001]
  • [Cites] Cell. 2002 May 17;109(4):509-21 [12086607.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2533-46 [12134088.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6278-88 [12414658.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):409-21 [12566431.001]
  • [Cites] J Cell Sci. 2004 Jul 15;117(Pt 16):3499-510 [15252126.001]
  • [Cites] J Cell Biol. 2004 Aug 30;166(5):697-708 [15337778.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:541-64 [14570581.001]
  • [Cites] FEBS Lett. 2004 Jan 2;556(1-3):211-5 [14706852.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Cell Motil Cytoskeleton. 2004 Apr;57(4):207-17 [14752805.001]
  • [Cites] Int J Cancer. 2004 May 10;109(6):909-18 [15027125.001]
  • [Cites] Neuron. 2004 Apr 8;42(1):37-49 [15066263.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):777-91 [18025308.001]
  • [Cites] Nat Cell Biol. 2007 Dec;9(12):1347-59 [18026093.001]
  • [Cites] J Cell Biol. 2007 Dec 17;179(6):1247-59 [18086920.001]
  • [Cites] Mol Cell. 2007 Dec 28;28(6):1071-82 [18158903.001]
  • [Cites] J Biol Chem. 2008 Apr 11;283(15):9814-9 [18283104.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7022-9 [15466195.001]
  • (PMID = 19081071.001).
  • [ISSN] 1878-1551
  • [Journal-full-title] Developmental cell
  • [ISO-abbreviation] Dev. Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA100324; United States / NCI NIH HHS / CA / 1-U54-CA112967; United States / NIGMS NIH HHS / GM / GM38511; United States / NCI NIH HHS / CA / CA100324; United States / NIGMS NIH HHS / GM / GM038511-12; United States / NIGMS NIH HHS / GM / GM58801; United States / NCI NIH HHS / CA / U54 CA112967-04; United States / NCI NIH HHS / CA / CA112967-04; United States / NCI NIH HHS / CA / U54 CA112967; United States / NCI NIH HHS / CA / CA100324-01; United States / NIGMS NIH HHS / GM / R01 GM058801; United Kingdom / Cancer Research UK / / ; United States / NCI NIH HHS / CA / R01 CA113395; United States / NIGMS NIH HHS / GM / R01 GM038511; United States / NCI NIH HHS / CA / P01 CA100324-01; United States / NIGMS NIH HHS / GM / R01 GM058801-10; None / None / / U54 CA112967-03; United States / NIGMS NIH HHS / GM / R01 GM038511-12; United States / NCI NIH HHS / CA / U54 CA112967-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enah protein, human; 0 / Microfilament Proteins; 0 / Protein Isoforms; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS87960; NLM/ PMC2637261
  •  go-up   go-down


7. Zhang Y, Li C, Fang X, Sun M: [Expression and clinical significance of matrix metalloproteinase-26 in non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Jun 20;11(3):420-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of matrix metalloproteinase-26 in non-small cell lung cancer.].
  • The aim of this study is to investigate the expression of MMP-26 protein in non-small cell lung cancer (NSCLC), and to analyze the correlations between MMP-26 and clinicopathological parameters.
  • METHODS: Seventy specimens of lung cancer, 30 of (para-cancer) normal lung tissues and 19 of pulmonary benign disease tissues were collected.
  • (1) The expression levels of MMP-26 protein in lung cancer tissues (64.3%) were significantly higher than that in paracancerous tissues (26.7%) and pulmonary benign disease tissues (31.3%) (P <0.01). (2) The expression levels of MMP-26 protein in lung cancer tissues were closely related to histological classification, grade of cell differentiation and TNM stages (P <0.05), but not related to age, sex, smoking history and tumor size (P >0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731946.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Liu Y, Wang J, Zhang H, Fu XM, Wang HQ: [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun;33(6):427-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of O6-methylguanine DNA methyltransferase and p53 in non-small cell lung cancer and the association with the prognosis].
  • OBJECTIVE: To investigate the expression and role of O(6)-methylguanine DNA methyltransferase (MGMT) and p53 in non-small cell lung cancer (NSCLC) and the association with prognosis.
  • METHODS: Immunohistochemical method was used to investigate the expression of MGMT and p53 in NSCLC specimens from 110 cases and in 20 cases of benign lung diseases as the control.
  • RESULTS: The positive expression of MGMT in NSCLC and benign lung diseases was 41.8% (46/110) and 80% (16/20) (χ(2) = 9.89, P < 0.05), respectively.
  • The positive expression of p53 in NSCLC and benign lung diseases were 56.4% (62/110) and 0% (0/20) (χ(2) = 21.551, P < 0.05), respectively.
  • They may participate in lung carcinomatosis, and may predict prognosis in patients with NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979814.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


9. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P: Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci; 2008 Aug;1137:180-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, the clinical relevance of circulating nucleosomes for diagnosis, staging, prognosis, and therapeutic monitoring of cancer is reviewed.
  • However, because of elevations of nucleosome levels in patients with benign diseases relevant for differential diagnosis, they are not suitable for cancer diagnosis.
  • Concerning tumor staging, nucleosome levels correlate with tumor stage and presence of metastases in gastrointestinal cancer, but not in other tumor types.
  • Prognostic value of circulating nucleosomes is found in lung cancer in univariate analyses, but not in multivariate analyses.
  • In addition, therapy outcome is already indicated by the nucleosomal course during the first week of chemo- and radiotherapy in patients with lung, pancreatic, and colorectal cancer as well as in hematologic malignancies.
  • Despite their non-tumor-specificity, kinetics of nucleosomes are valuable markers for the early estimation of therapeutic efficacy and may be helpful to adapting early cancer therapy in the future.
  • [MeSH-minor] Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Prognosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837945.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macromolecular Substances; 0 / Nucleosomes
  • [Number-of-references] 68
  •  go-up   go-down


10. Rabban JT, Zaloudek CJ, Shekitka KM, Tavassoli FA: Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. Am J Surg Pathol; 2005 Oct;29(10):1348-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors.
  • Inflammatory myofibroblastic tumor (IMT) is an indolent spindle cell proliferation that can histologically resemble various malignant mesenchymal neoplasms; however, it generally behaves as a benign or locally recurrent tumor.
  • Most IMTs involve the lung, mesentery, omentum, or retroperitoneum.
  • The three other tumors grew as bulky myometrial masses with focally irregular borders and infiltrated the endometrium, parametrium, or cervical stroma.
  • A lymphoplasmacytic infiltrate was present in all of the tumors, and most had a myxoid background.
  • Mitotic activity ranged from 0 to 2 mitotic figures per 10 high power fields (HPF) except in one tumor that focally had up to 8 mitotic figures per 10 HPF.
  • IMTs should be differentiated from aggressive uterine mesenchymal tumors because they can be treated conservatively and have a more favorable prognosis.
  • [MeSH-minor] Adolescent. Adult. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Protein-Tyrosine Kinases / metabolism. Receptor Protein-Tyrosine Kinases. Sarcoma / metabolism. Sarcoma / pathology

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160478.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


11. Teppone M, Avakyan R: Extremely high-frequency therapy in oncology. J Altern Complement Med; 2010 Nov;16(11):1211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: At the early stage of these studies, efficacy and safety of millimeter electromagnetic radiation (extremely high frequency [EHF]) was proved for various types of malignant tumors.
  • The majority of the further studies demonstrated the high efficacy and safety of millimeter wave radiation in treating patients suffering from both benign and malignant tumors.
  • RESULTS: Developments led to treatment on skin melanoma, cancer of the ear-nose-throat, bowel and breast cancer, cancer of the uterus, lung, and stomach, solid tumors, as well as lymphoma.
  • (3) prevention of metastases, relapses, and dissemination of the tumor;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973733.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


12. Chaplin A, Conrad DM, Tatlidil C, Jollimore J, Walsh N, Covert A, Pasternak S: Primary cutaneous PEComa. Am J Dermatopathol; 2010 May;32(3):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of the excisional specimen revealed a dermal tumor composed of nests of epithelioid cells exhibiting clear cytoplasm.
  • The tumor showed an infiltrative border.
  • Immunohistochemical evaluation revealed that the tumor cells were positive for HMB-45 and microftalmia associated transcription factor (MITF).
  • The tumor cells were negative for S-100 protein, alfa smooth muscle actin, HHF-35, and various cytokeratins.
  • Pecomas are rare, recently described mesenchymal tumors composed of perivascular epithelioid cells.
  • They constitute a spectrum of lesions in different organs including angiomyolipoma of the kidney and liver, sugar tumor of the lung, lymphangiomatosis, and lymphangiomyoma.
  • Follow-up data is limited but they appear to behave in a benign fashion.
  • We report an additional case with the goal of alerting dermatopathologists to this distinctive unusual neoplasm.
  • [MeSH-minor] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy. Desmin / analysis. Female. Humans. Leg. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Neoplasm Proteins / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139753.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MITF protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  •  go-up   go-down


13. Hu WD, Liao MY, Chen JK: [Clinical analysis of solitary pulmonary nodule measuring less than 10 mm]. Ai Zheng; 2006 Feb;25(2):217-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Lung cancer is a malignant disease with high incidence and mortality, and its prognosis is to large degree determined by early diagnosis and treatment.
  • X-ray chest film and computed tomography (CT) are important means to discover and diagnose lung cancer.
  • The differences between benign and malignant lesions were compared.
  • Imaging features of SPN of lung cancer were summarized.
  • RESULTS: Of the 102 cases of SPN measuring less than 10 mm, 66 (64.7%) were benign lesions, 25 (24.5%) were primary lung cancer, and 11 (10.8%) were metastatic lung cancer.
  • The benign lesions included inflammatory pseudotumor, benign tumor, lung tuberculosis, and so on.
  • Primary lung cancers, including 6 advanced cases (stage IIA and higher stage), had several radiological features different from benign nodules, such as ill-defined margins, speculation, bronchus or vessel involvement.
  • Also, the enhanced CT value was higher in malignant nodules than in benign nodules except inflammation pseudotumor.
  • The SPNs of metastatic lung cancer had similar radiologic features to those of primary lung cancer.
  • CONCLUSION: SPNs measuring less than 10 mm are mainly composed of benign lung tumor and primary lung cancer.
  • [MeSH-major] Lung Neoplasms. Solitary Pulmonary Nodule
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / secondary. Female. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / radiography. Humans. Lung Diseases / pathology. Lung Diseases / radiography. Male. Middle Aged. Retrospective Studies. Smoking. Tomography, X-Ray Computed / methods. Tuberculosis, Pulmonary / pathology. Tuberculosis, Pulmonary / radiography

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16480590.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


1
Advertisement
4. Kurkcuoglu IC, Demircan S, Kurul IC, Demirag F: Endobronchial lipomatous hamartoma. Asian Cardiovasc Thorac Ann; 2005 Dec;13(4):372-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hamartomas are the most common benign neoplasm of the lung, occurring in the parenchyma or sometimes within the bronchi.
  • Reported is a case of a 64-year-old male patient with an endobronchial tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304229.001).
  • [ISSN] 0218-4923
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Yamagishi S, Koizumi K, Hirata T, Hirai K, Kurita J, Shimizu K: Experience of thoracoscopic extirpation of intrapulmonary lymphangioma. Jpn J Thorac Cardiovasc Surg; 2005 Jun;53(6):313-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiologically, we diagnosed this lesion as a benign cystic tumor in the lung.
  • As this suggested a benign bronchogenic cyst, we performed extirpation of the cyst under thoracoscopy.
  • [MeSH-major] Lung Neoplasms / surgery. Lymphangioma / surgery. Thoracoscopy

  • Genetic Alliance. consumer health - Lymphangioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997754.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Jin FG, Fu EQ, Xie YH, Li WP, Nan YD, Liu W, Sun RL: [The application of combined interventional procedures for the management of intractable central airway stenosis]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jan;33(1):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, two or more procedures were combined to manage complicated airway stenosis according to stenosis causes, types, position, degree and duration, or functions of distal lung tissue and airway.
  • Among 23 cases benign disease, including 4 benign tumor, 15 tuberculosis and 4 other granulomatosis, 5 cases with various degrees of restenosis needed further interventional therapy after 3 months of follow up and effective rate was 78.3% (18/23).
  • Patients with malignant tumor were not followed up for long term.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20368019.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


17. Banerjee S, Byrd JN, Gianino SM, Harpstrite SE, Rodriguez FJ, Tuskan RG, Reilly KM, Piwnica-Worms DR, Gutmann DH: The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo. Cancer Res; 2010 Feb 15;70(4):1356-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
  • Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome in which affected individuals develop benign and malignant nerve tumors.
  • The NF1 gene product neurofibromin negatively regulates Ras and mammalian target of rapamycin (mTOR) signaling, prompting clinical trials to evaluate the ability of Ras and mTOR pathway inhibitors to arrest NF1-associated tumor growth.
  • To discover other downstream targets of neurofibromin, we performed an unbiased cell-based high-throughput chemical library screen using NF1-deficient malignant peripheral nerve sheath tumor (MPNST) cells.
  • [MeSH-minor] Animals. Animals, Newborn. Cells, Cultured. Chromones / pharmacology. Enzyme Inhibitors / pharmacology. Gene Expression Regulation / drug effects. Genes, Tumor Suppressor / physiology. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Nude. Mice, Transgenic. Morpholines / pharmacology. Protein-Serine-Threonine Kinases / metabolism. Signal Transduction / drug effects. Signal Transduction / genetics. TOR Serine-Threonine Kinases. Triterpenes / pharmacology. Xenograft Model Antitumor Assays


18. Machida K, Urano K, Yoshimura M, Tsutsumi H, Nomura T, Usui T: Carcinogenic comparative study on rasH2 mice produced by two breeding facilities. J Toxicol Sci; 2008 Oct;33(4):493-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the MNU group, MNU-induced tumor death occurred from 9 to 12 weeks after administration, and the final survival rate for both facilities was 6.7%.
  • In the pathological examination, only benign tumors of lungs, spleen, forestomach and skin were observed in a few mice in the vehicle group of both facilities.
  • Although lung adenoma and skin papilloma/keratoacanthoma, which are major MNU induced tumors in this strain, were observed in several mice from both facilities, no significant differences were found.

  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827450.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinogens; 684-93-5 / Methylnitrosourea
  •  go-up   go-down


19. Donthineni R, Boriani L, Ofluoglu O, Bandiera S: Metastatic behaviour of giant cell tumour of the spine. Int Orthop; 2009 Apr;33(2):497-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic behaviour of giant cell tumour of the spine.
  • Lung metastases from giant cell tumours (GCT) of the spine have not been specifically addressed in the literature.
  • Between 1970 and 2006, we identified seven cases (three females and four males) of lung metastases from a total of 51 cases of GCT of the spine (13.7%).
  • The treatments for the lung nodules consisted of metastectomy in two and chemotherapy in six patients.
  • Our series shows a higher metastatic rate from spine GCT as compared to those from the extremities, but the overall behaviour and treatment outcomes of the lung metastases are similar.
  • When there is a recurrence of GCT, with or without metastases, the local and possibly the metastases should be biopsied to confirm the original diagnosis.
  • Progression of benign GCT into an aggressive sarcoma has been documented, and the method of management should be altered.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):499-504 [16909252.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jan;75(1):148-54 [8421014.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Int Orthop. 1996;20(3):172-6 [8832321.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):649-51 [9766596.001]
  • [Cites] Cancer. 1964 Apr;17:461-72 [14136529.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 18461324.001).
  • [ISSN] 1432-5195
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899057
  •  go-up   go-down


20. Weissferdt A, Langman G: An intracapsular carcinoma ex pleomorphic adenoma with lung metastases composed exclusively of benign elements: histological evidence of a continuum between metastasizing pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Pathol Res Pract; 2010 Jul 15;206(7):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An intracapsular carcinoma ex pleomorphic adenoma with lung metastases composed exclusively of benign elements: histological evidence of a continuum between metastasizing pleomorphic adenoma and carcinoma ex pleomorphic adenoma.
  • Malignant mixed tumors of the salivary glands, encompassing carcinoma ex pleomorphic adenoma (ca ex PA), carcinosarcoma and metastasizing pleomorphic adenoma (mPA), are rare neoplasms.
  • When the malignant component does not breach the capsule of the parent PA, the lesion is termed intracapsular ca ex PA, a neoplasm which is thought to have no metastatic potential.
  • Metastatic deposits of ca ex PA are composed exclusively of malignant elements or mixed benign and malignant components.
  • We describe the case of a 62-year-old female with an intracapsular ca ex PA of the buccal mucosa with subsequent metastases to the lung.
  • The metastatic deposits resembled benign PA with no histological evidence of malignancy.
  • This pattern of spread is described with mPA, an entity that caused controversy in the past regarding its exact classification as a benign or malignant tumor.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Lung Neoplasms / secondary. Mouth Mucosa / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19665316.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Freedman LS, Oberman B, Sadetzki S: Using time-dependent covariate analysis to elucidate the relation of smoking history to Warthin's tumor risk. Am J Epidemiol; 2009 Nov 1;170(9):1178-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using time-dependent covariate analysis to elucidate the relation of smoking history to Warthin's tumor risk.
  • The authors aimed to elucidate the relation of the time-dependent smoking history parameters--age at smoking initiation and smoking intensity, duration, and latency--to the risk of Warthin's tumor, a benign tumor of the salivary gland for which cigarette smoking is a strong risk factor.
  • They studied 117 cases of Warthin's tumor and 336 matched controls included in an Israeli nationwide case-control study of parotid gland tumors conducted from 2002 to 2003 by using the Cox regression model with time-dependent covariates, with age as the time axis.
  • The relation of smoking variables to Warthin's tumor agrees with the patterns reported for lung cancer.

  • Genetic Alliance. consumer health - Warthin's tumor.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755633.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Varazashvili Varazi LM, Osmanova VR, Barkadze KI: [Study of serum levels of magnesium in the patients with malignant tumors]. Georgian Med News; 2006 Jul;(136):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of serum levels of magnesium in the patients with malignant tumors].
  • The main goal of the study was the evaluation of serum levels of magnesium in the practically healthy persons (control group), the patients with different malignant tumors (abdominal, pulmonary, uterus, breast, esophagus, rectum), as well as benign tumors of the breast/the uterus and the inflammatory pulmonary diseases.
  • It has been found that, in comparison with norm (23.9 mkg/ml), there is statistically significant increase in serum mean levels of Mg in the patients with malignant tumors of almost all sites investigated.
  • Abdominal/breast and lung malignant tumors are exclusive from this point of view: we have found that Mg content is near the normal mean levels in the former cases (24.7 mkg/ml and 25.3 mkg/ml, respectively) and below the average normal value in lung malignant tumors (20.5 mkg/ml).
  • It has been ascertained that there is no significant difference between the serum average levels of Mg in the control group and in the patients with pulmonary inflammatory diseases, as well as between the Mg-content in practically health persons and in those with breast benign tumors.
  • Thus, assessment of serum Mg levels seems to be useful in differential diagnosis in oncopulmonary and oncomammology clinics.
  • [MeSH-major] Biomarkers, Tumor / blood. Magnesium / blood. Neoplasms / blood
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905841.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; I38ZP9992A / Magnesium
  • [Number-of-references] 14
  •  go-up   go-down


23. Kluijt I, de Jong D, Teertstra HJ, Axwijk PH, Gille JJ, Bell K, van Rens A, van der Velden AW, Middelton L, Horenblas S: Early onset of renal cancer in a family with Birt-Hogg-Dubé syndrome. Clin Genet; 2009 Jun;75(6):537-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé syndrome is a hereditary syndrome characterized by benign disease of skin and lungs and a risk of malignant renal tumors.
  • [MeSH-major] Family. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Base Sequence. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / genetics. DNA / analysis. Female. Humans. Lung Diseases / diagnosis. Lung Diseases / genetics. Male. Middle Aged. Molecular Sequence Data. Pedigree. Pneumothorax / diagnosis. Pneumothorax / genetics. Proto-Oncogene Proteins / genetics. Sequence Deletion. Skin Abnormalities / diagnosis. Skin Abnormalities / genetics. Syndrome. Tumor Suppressor Proteins / genetics


24. Feng F, Nie G, Wu Y, Wu Y: [Comparison and analysis of three classifying models for discrimination of lung cancer established by 6 tumor markers]. Wei Sheng Yan Jiu; 2009 Jul;38(4):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison and analysis of three classifying models for discrimination of lung cancer established by 6 tumor markers].
  • OBJECTIVE: To distinguish lung cancer by detecting 6 tumor markers in serum and establishing three classifying models of artificial neural networks (ANN), decision tree (CART), Fisher discrimination analysis, and to compare the differences among three models.
  • METHODS: The levels of serum CEA, gastrin, NSE, sialic acid (SA), Cu/ Zn, Ca in 50 healthy individuals, 40 patients with lung benign disease and 50 patients with lung cancers were detected by means of radioimmunology, spectrophotometry, atomic absorption spectrophotometry, respectively, and then developed ANN, CART and Fisher discrimination analysis models.
  • CONCLUSION: The effects of ANN, CART models established by 6 tumor markers were better than that of Fisher discrimination analysis in discrimination of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Decision Trees. Discriminant Analysis. Lung Neoplasms / diagnosis. Neural Networks (Computer)
  • [MeSH-minor] Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Diagnosis, Differential. Gastrins / blood. Humans. N-Acetylneuraminic Acid / blood. ROC Curve. Sensitivity and Specificity. Small Cell Lung Carcinoma / blood. Small Cell Lung Carcinoma / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19689074.001).
  • [ISSN] 1000-8020
  • [Journal-full-title] Wei sheng yan jiu = Journal of hygiene research
  • [ISO-abbreviation] Wei Sheng Yan Jiu
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Gastrins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


25. Sun BL, Zhu L, Ding WF, Jing RR, Chu SP, Wang HM: [The diagnostic value of quantitative measurement of a proliferation-inducing ligand mRNA in sputum samples from lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Mar;32(3):182-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnostic value of quantitative measurement of a proliferation-inducing ligand mRNA in sputum samples from lung cancer patients].
  • OBJECTIVE: To establish a real-time fluorescence quantitative polymerase chain reaction (RFQ-PCR) method for quantifying a proliferation-inducing ligand (APRIL) mRNA in sputum samples from patients with non-small cell lung cancer (NSCLC), and to evaluate its role in the diagnosis of NSCLC.
  • METHODS: Seventy-one cases of NSCLC and 62 cases of benign pulmonary disease were enrolled in this study from August 2007 to May 2008 in Affiliated Hospital of Nantong University, Jiangsu.
  • The expression of APRIL mRNA in tumor sputum was higher than that in benign pulmonary disease and healthy volunteers (t = 10.50, 11.32, P < 0.01).
  • The positive rate for APRIL mRNA expression was 81.7% (58 of 71) in sputum samples of NSCLC, 3.2% (2/62) in benign pulmonary disease and 1.5% (1/65) in healthy volunteers when cut-off values for positivity were set at the x(-) +/- 2 s of mRNA expression in health volunteers.
  • The level of APRIL mRNA of NSCLC was not related to sex, age, smoking status, TNM stage and lymph node metastasis (P > 0.05, respectively), but was related to pathology subtype and the location of tumors (P < 0.05, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Polymerase Chain Reaction / methods. Sputum / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Ligands. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / analysis. Sensitivity and Specificity. Tumor Necrosis Factor Ligand Superfamily Member 13 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575936.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ligands; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


26. Bossert T, Walther T, Vondrys D, Gummert JF, Kostelka M, Mohr FW: Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. Tex Heart Inst J; 2006;33(1):88-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Echocardiography revealed a left ventricular tumor.
  • The tumor was resected through a left ventriculotomy, and the left ventricle was reconstructed after a partial ventriculectomy Histologic investigation showed a completely resected benign fibroma.

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2001 Apr;71(4):1354-6 [11308193.001]
  • [Cites] Ann Thorac Surg. 2003 Apr;75(4):1306-8 [12683582.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1986 Jul;112(7):773-5 [3707741.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Am Heart J. 1997 Dec;134(6):1107-14 [9424072.001]
  • [Cites] Pediatr Cardiol. 1991 Apr;12(2):118-20 [1866331.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Nov;108(5):862-70 [7967668.001]
  • [Cites] J Heart Lung Transplant. 1995 Mar-Apr;14(2):382-6 [7779860.001]
  • [Cites] Thorac Cardiovasc Surg. 1990 Aug;38 Suppl 2:176-82 [2237899.001]
  • (PMID = 16572881.001).
  • [ISSN] 0730-2347
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1413607
  •  go-up   go-down


27. Waalkes MP, Liu J, Kasprzak KS, Diwan BA: Metallothionein-I/II double knockout mice are no more sensitive to the carcinogenic effects of nickel subsulfide than wild-type mice. Int J Toxicol; 2005 Jul-Aug;24(4):215-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no differences in the incidence of spontaneous tumors in MT-null and WT mice.
  • Nickel-treatment had no effect on total lung tumor incidence, although some phenotypic-specific differences occurred in the proportion of benign and malignant pulmonary tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRINICKEL DISULFIDE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126615.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 12035-72-2 / nickel subsulfide; 7OV03QG267 / Nickel; 9038-94-2 / Metallothionein
  •  go-up   go-down


28. Tsunezuka Y, Shimizu Y, Tanaka N, Takayanagi T, Kawano M: Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size. World J Surg; 2007 Feb;31(2):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography in relation to Noguchi's classification for diagnosis of peripheral non-small-cell lung cancer 2 cm or less in size.
  • BACKGROUND: F-18 fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) scanning has become a critically important tool in diagnosis and management of non-small-cell lung cancer.
  • However, the effectiveness of (18)F-FDG-PET as a diagnostic tool for small-sized lung cancer is controversial.
  • The purpose of this study was to examine the accuracy of( 18)F-FDG-PET in relation to Noguchi's classification in the diagnosis of small peripheral non-small-cell lung cancer.
  • METHODS: Between January 2003 and April 2006, 150 patients with peripheral lung lesions who were undergoing chest computed tomography (CT),( 18)F-FDG-PET, and operation were analyzed.
  • RESULTS: Eighty-three patients had malignant lesions, and 67 patients had benign lesions.
  • In 37 patients with peripheral lung cancer measuring 2.0 cm or less in the greatest diameter, the sensitivity was 51.4% and the specificity was 51.9%.
  • CONCLUSION: The accuracy of( 18)F-FDG-PET is generally low in distinguishing malignancy from benign lesions in small lesions (<2.0-cm diameter).
  • The significance of PET as a diagnostic tool is small, especially when the tumor has a ground-glass component at a high rate.
  • The sensitivity of PET is high in small invasive carcinomas without a BAC component, but it is difficult to distinguish carcinoma from benign tumor from its image.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / diagnostic imaging. Carcinoma, Non-Small-Cell Lung / diagnostic imaging. Fluorodeoxyglucose F18. Lung Neoplasms / diagnostic imaging. Mixed Tumor, Malignant / diagnostic imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):278-84 [12167787.001]
  • [Cites] Respiration. 2003 Sep-Oct;70(5):500-6 [14665776.001]
  • [Cites] Ann Nucl Med. 2004 Feb;18(1):23-8 [15072180.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8396-405 [16293870.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1166-73 [12192561.001]
  • [Cites] Lung Cancer. 2003 Dec;42(3):303-10 [14644518.001]
  • [Cites] Chest. 2006 Feb;129(2):393-401 [16478857.001]
  • [Cites] Ann Thorac Surg. 2004 Sep;78(3):1017-23; discussion 1017-23 [15337041.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):426-31 [16513611.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):956-60; discussion 961 [11269480.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1075-84 [9508193.001]
  • (PMID = 17219276.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Zhang J, Chen AP, Wang B, Zhao SP, Liu LZ, Dai SZ: [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer]. Ai Zheng; 2008 Dec;27(12):1331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Abnormal expression and activation of epidermal growth factor receptor (EGFR), which is closely related to the recurrence and poor prognosis of ovarian cancer, can promote chemotherapy resistance of tumor cells.
  • Lung resistance protein (LRP), a multidrug resistance protein causing platinum-resistance, is an independent factor in predicting chemotherapy sensitivity to ovarian cancer.
  • METHODS: Expressions of EGFR and LRP in 76 specimens of ovarian malignant tumor, nine borderline tumor, 17 benign tumor and 15 normal ovary were studied using immunohistochemistry.
  • RESULTS: The positive rates of EGFR and LRP in malignant specimens (73.68% and 71.79%) were significantly higher than those in normal and benign ones (P <0.01).
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / pharmacology. Cystadenocarcinoma, Mucinous / drug therapy. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenoma, Mucinous / drug therapy. Cystadenoma, Mucinous / metabolism. Cystadenoma, Mucinous / pathology. Cystadenoma, Serous / drug therapy. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate


30. Ponti G, Luppi G, Martorana D, Rossi G, Losi L, Bertolini F, Sartori G, Pellacani G, Seidenari S, Boni E, Neri TM, Silini E, Tamburini E, Maiorana A, Conte PF: Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting. Oncol Rep; 2010 Feb;23(2):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor and other primary metachronous or synchronous neoplasms as a suspicion criterion for syndromic setting.
  • Gastrointestinal stromal tumors (GISTs) may be sporadic or inherited.
  • The present study was designed to analyze the synchronous and metachronous tumors developed among GIST patients assessed by our institution for GIST Syndrome setting recognition.
  • The development of GIST associated with other neoplasms is common and diagnosis of peculiar benign associated-neoplasms warrants the search for familial cancer susceptibility.
  • In particular, syndromic or familial settings have to be suspected in the presence of neurofibroma or lung chordoma in C-KIT and PDGFRA negative GIST patients.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Aged. Carney Complex / complications. Carney Complex / genetics. DNA Mutational Analysis / methods. Diagnosis, Differential. Female. Genes, Neurofibromatosis 1. Humans. Male. Middle Aged. Neurofibromatoses / complications. Neurofibromatoses / diagnosis. Neurofibromatoses / genetics. Pedigree. Retrospective Studies. Syndrome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043105.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


31. Herawi M, Epstein JI: Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol; 2006 Jun;30(6):694-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases.
  • Specialized stromal tumors of the prostate encompass stromal sarcoma and stromal tumors of uncertain malignant potential (STUMP).
  • The histology in the 36 cases of STUMP not associated with sarcoma were as follows: 25 composed of stroma with scattered cytologically atypical cells associated with benign glands; 8 resembling glandular-stromal hyperplasia but with hypercellular stroma; 6 with extensive myxoid stroma; and 1 with phyllodes pattern.
  • In 3 of these cases, tumors were adherent to the rectum at the time of resection.
  • Five cases of STUMP showed local tumor growth: 1 case increased in size from 6 to 7.5 cm in 3 years and 4 cases recurred frequently necessitating multiple TURs of the prostate (n=2, n=3, n=3, n=3) over 1.1, 2, 7, and 8 years, respectively.
  • Fourteen patients with STUMP underwent radical prostatectomy (RP) soon after diagnosis; of these, 12 were organ confined where the tumor size ranged from 0.7 to 7.5 cm (mean 2.7 cm); 2 cases with a history of a 28 g TUR and a 275 g enucleation showed no residual tumor in the RP specimen.
  • One man was alive with metastasis to the lung 10 months after RP, 1 man was alive at 280 months with multiple metastases, and another died of disease at 115 months.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / therapy. Prostatic Hyperplasia / pathology. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16723846.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, Naccarato AG, Borsari S, Lemmi M, Berti P, Miccoli P, Pinchera A, Marcocci C: Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol; 2007 May;156(5):547-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
  • The aim of our study was to extend parafibromin studies in a series of benign and malignant parathyroid tumors and cross-validate the results of immunohistochemistry with those of HRPT2 analysis.
  • DESIGN AND PATIENTS: We performed parafibromin and cyclin D1 immunostaining and HRPT2 gene analysis using loss of heterozygosity studies and sequencing analysis in parathyroid specimens from 11 patients with carcinoma (eleven primary tumors, one skin, and four lung metastases), 22 with sporadic adenomas, and 4 with atypical adenomas.
  • In clinical practice, these tests could be particularly useful in the subset of parathyroid tumors with equivocal histological examination.

  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17468190.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDC73 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


33. Dhillon MS, Prasad P: Multicentric giant cell tumour of bone. Acta Orthop Belg; 2007 Jun;73(3):289-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric giant cell tumour of bone.
  • Although giant cell tumour (GCT) is seen quite frequently, multicentric giant cell tumour (MCGCT) is a rare entity occurring in less than 1% of patients with GCT.
  • The pathogenesis of MCGCT is debated; various mechanisms have been postulated, including contiguous spread, iatrogenic tumour cell seeding, benign metastasis, malignant transformation and de novo formation.
  • Four lung metastases and two histologically malignant lesions were found.
  • [MeSH-major] Bone Neoplasms. Giant Cell Tumor of Bone
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715717.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


34. Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res; 2006 May 15;66(10):5295-303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling.
  • Meningiomas are the second most common brain tumor in adults, yet comparatively little is presently known about the dysregulated growth control pathways involved in their formation and progression.
  • One of the most frequently observed genetic changes in benign meningioma involves loss of protein 4.1B expression.
  • In this report, we show that protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 (DAL-1) expression in meningioma cells in vitro results in JNK activation, which requires the sequential activation of Src, Rac1, and JNK.
  • [MeSH-major] JNK Mitogen-Activated Protein Kinases / metabolism. Membrane Proteins / metabolism. Meningioma / enzymology. Meningioma / pathology. Tumor Suppressor Proteins / metabolism. rac1 GTP-Binding Protein / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16707455.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / EPB41L3 protein, human; 0 / Membrane Proteins; 0 / Microfilament Proteins; 0 / RAC1 protein, human; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / mitogen-activated protein kinase kinase kinase 11; EC 3.6.5.2 / rac1 GTP-Binding Protein
  •  go-up   go-down


35. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I: Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology; 2009 Jul;14(5):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with malignant pleural effusions had higher PF and lower serum OPN concentrations than those with benign disease.
  • [MeSH-major] Lung Diseases / metabolism. Lung Neoplasms / metabolism. Osteopontin / metabolism. Pleural Effusion / metabolism. Pleural Effusion, Malignant / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pneumonia / complications. Pneumonia / diagnosis. Pneumonia / metabolism. Prospective Studies. Tuberculosis / complications. Tuberculosis / diagnosis. Tuberculosis / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476604.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


36. Zhang Y, Gomez-Fernandez CR, Jorda M, Ganjei-Azar P: Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature. Diagn Cytopathol; 2009 Nov;37(11):828-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration (FNA) and pleural fluid cytology diagnosis of benign metastasizing pleomorphic adenoma of the parotid gland in the lung: a case report and review of literature.
  • Lesions that contain abundant benign myoepithelial cells, including pleomorphic adenomas of salivary gland origin, may present a diagnostic challenge in fine-needle aspiration (FNA) specimens.
  • Benign metastasizing pleomorphic adenoma is a rare neoplasm, in which the benign appearing pleomorphic adenoma, without any histological evidence of malignancy, metastasizes to distant sites including lung.
  • In the absence of clinical history of a pre-existing myoepithelial neoplasm, the presence of myoepithelial cells in the lung or any other organs besides salivary glands may create diagnostic difficulty.
  • Here we present the cytologic findings of such a metastatic tumor found in the lung FNA and pleural fluid specimens from a 64-year-old woman, with a history of local recurrent salivary gland pleomorphic adenomas, who presented with multiple bilateral pulmonary nodules and pleural effusion.
  • The diagnosis of benign metastasizing pleomorphic adenoma was made based on clinical information and cytomorphology, and confirmed by immunocytochemistry.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Biopsy, Fine-Needle. Lung Neoplasms / secondary. Parotid Neoplasms / pathology. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582818.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


37. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


38. Bodtger U, Pedersen JH, Skov BG, Clementsen P: Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm. Clin Respir J; 2009 Apr;3(2):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant solitary fibrous tumour of the pleura: a rare but usually benign intrathoracic neoplasm.
  • BACKGROUND: Low forced expiratory volume (FEV(1)) and low performance status usually preclude surgical treatment of lung neoplasms.
  • METHODS: A case report of an 83-year-old women with progressing dyspnoea secondary to a huge left-side neoplasm.
  • RESULTS: Work-up reveal an FEV(1) of 0.4 L, and a giant solitary fibrous tumor of the pleura.
  • The tumor was surgically removed in toto without complications: weighting approximately 3 kg, and benign histology.
  • CONCLUSION: Safe and curative surgery is possible in patients with extrapulmonal neoplasm despite poor FEV(1).
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Aged, 80 and over. Biopsy, Needle. Dyspnea / diagnosis. Dyspnea / etiology. Female. Follow-Up Studies. Humans. Immunohistochemistry. Postoperative Care / methods. Preoperative Care / methods. Radiography, Thoracic. Severity of Illness Index. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298386.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Zhang Y, Miao Y, Yi J, Wang R, Chen L: Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer. Clin Lung Cancer; 2010 Jul 1;11(4):264-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
  • BACKGROUND: Deleted in lung and esophageal cancer 1 (DLEC1) gene was a new candidate tumor suppressor gene.
  • We determined the expression level and methylation status of DLEC1 in non-small-cell lung cancer (NSCLC), and the DLEC1 methylation in plasma DNA as a biomarker for NSCLC was further evaluated.
  • PATIENTS AND METHODS: The study population enrolled 78 paired NSCLC specimens and adjacent normal tissues and 25 benign pulmonary lesions.
  • RESULTS: Hypermethylation of DLEC1 was found in 41% (32/78) of NSCLC tissues, which was significantly higher than that of adjacent normal tissues (3.8%; 3/78) and benign lesions (0/25; P < .001).
  • Methylated DLEC1 was detected in 35.9% (28/78) of plasma samples from NSCLC patients and only 2% (1/50) in cancer-free controls, and the concordance of DLEC1 methylation status in plasmas and corresponding tumor tissues was good.
  • CONCLUSION: DLEC1 is silenced by promoter methylation in NSCLC specimens and is widely expressed in adjacent normal tissues and benign control samples.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Epigenesis, Genetic. Lung Neoplasms / genetics. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Female. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Middle Aged. Prognosis. Survival Rate. Tumor Cells, Cultured


40. Deniz H, Kibar Y, Güldür ME, Bakir K: Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations? Pathol Res Pract; 2009;205(11):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
  • Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis.
  • The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations.
  • In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation.
  • The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA.
  • Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations.
  • We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antibodies, Monoclonal. Lung / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Pleura / metabolism. Pleural Neoplasms / diagnosis. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19573998.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  •  go-up   go-down


41. Luong TV, Salvagni S, Bordi C: Presacral carcinoid tumour. Review of the literature and report of a clinically malignant case. Dig Liver Dis; 2005 Apr;37(4):278-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presacral carcinoid tumour. Review of the literature and report of a clinically malignant case.
  • Carcinoid tumours arising in the presacral region are extremely rare and they are usually benign.
  • We report the case of a 37-year-old black man with a clinically malignant carcinoid tumour (well differentiated endocrine carcinoma) occurring in a sacrococcygeal teratoma and already metastasised to pelvic nodes, liver and bone at the time of the initial diagnosis.
  • [MeSH-major] Carcinoid Tumor / pathology
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Pelvic Floor / pathology. Pelvic Floor / radiography. Pelvic Neoplasms / secondary. Phosphopyruvate Hydratase / analysis. Sacrococcygeal Region. Synaptophysin / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788213.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 15
  •  go-up   go-down


42. Zhang XM, Shen CY, Li W, Zhang XM: [Surgical treatment of tumor invading important vessel]. Zhonghua Wai Ke Za Zhi; 2007 Aug 1;45(15):1044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of tumor invading important vessel].
  • OBJECTIVE: To sum up preliminary experience of successful resection of tumor involving important vessel in 77 cases.
  • The tumor involving thoraco-abdominal cavity was in one case with malignant neuroblastoma.
  • The tumor from retro-peritoneum invaded into the whole inferior vena cava (IVC), and into two-thirds of the right atrium.
  • Tumor located in thoracic cavity were in 13 cases including IVC leiomyosarcoma in 2 cases, thymic carcinoma in 3 cases, malignant thymoma in 4 cases, malignant seminoma of superior mediastinum in 1 case, malignant lymphoma in 1 case, lung cancer in 2 cases.
  • The tumor located in abdominal cavity were in 24 cases including renal carcinoma with tumor thrombi in 11 cases, inflammatory pseudotumor of retro-peritoneum in 4 cases, malignant fibrous histiocytoma of retro-peritoneum in 1 case, non-Hodgkin's disease of retro-peritoneum in 1 case, lymph metastasis of retro-peritoneum in 2 cases, paraganglion tumor of the right adrenal gland in 1 case, ampullary carcinoma in 1 case, leiomyosarcoma of abdominal IVC in 1 case, leiomyosarcoma of pelvic cavity and IVC in 1 cases, fibrosarcoma of pelvic cavity in 1 case.
  • Tumor located in four extremities in 6 cases including osteogenic sarcoma in 3 cases, vascular endotheliosarcoma of the left iliac fossa in 1 case, neurofibroma of the left upper extremity in 1 case, lymphoma of double groin in 1 case.
  • Tumor located in neck in 33 cases including carotid body tumor in 32 cases and neurofibroma of the left upper extremity in 1 case.
  • RESULTS: Complete resection of tumor was in 72 cases, with a rate of 93.5%, palliative resection of tumor was in 5 cases with a rate of 6.5%.
  • Temporary shunt of carotid artery for neck tumor was used in 18 cases.
  • No death occurred for benign tumor.
  • CONCLUSION: The radical resection rate for tumor involving important vessel may be improved with the help of vascular technique.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome. Vena Cava, Inferior / pathology. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005586.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Altamirano-Ley J, Estrada-Sánchez GR, Ochoa-Carrillo FJ: [Positron emission tomography and computed tomography (PET/CT) in lung cancer]. Cir Cir; 2007 Jul-Aug;75(4):303-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography and computed tomography (PET/CT) in lung cancer].
  • [Transliterated title] Tomografía por emisión de positrones y tomografía computarizada (PET/CT) en carcinoma de pulmón.
  • BACKGROUND: Lung cancer is the most frequent cause of death due to neoplasm in Western populations, with >660,000 new diagnoses of lung cancer per year according to the World Health Organization.
  • METHODS: We undertook this study to emphasize the role of positron emission tomography to all health care professionals involved in lung cancer diagnosis.
  • One relatively common cause of false positives is the vocal cord and adjacent muscles contralateral and compensatory to the lung lesion that show an increased uptake of (18)FDG because of lesions in the laryngeal nerve by the tumor or secondary to surgery.
  • CONCLUSIONS: There is sufficient scientific evidence pointing to the usefulness of PET studies and its evolution to PET/CT, especially in patients with lung cancer.
  • This can resolve doubts by the oncologist and patient when there is a suspicious malignant lesion by the following: characterizing solitary pulmonary nodules (benign or malignant), localizing the optimal site for the biopsy, diagnosis of the primary tumor for initial staging, evaluation of mediastinal involvement and distant metastasis, evaluate and restage residual tumor, assessment of recurrence, monitoring response, prognostic prediction and radiotherapy planning.
  • [MeSH-major] Lung Neoplasms / diagnosis. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Metastasis. Neoplasm Staging. Solitary Pulmonary Nodule / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053364.001).
  • [ISSN] 0009-7411
  • [Journal-full-title] Cirugía y cirujanos
  • [ISO-abbreviation] Cir Cir
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 50
  •  go-up   go-down


44. Zheng JP, Shao GL, Chen YT, Fan SF, Yang JM: [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):786-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-four malignant lesions were confirmed by pathology, including 30 adenocarcinomas, 19 squamous cell carcinomas, 5 unclassified malignant tumors, 3 small cell carcinomas, 2 malignant giant cell tumors of bone, 2 hepatocellular carcinomas and 3 false negative lesions which were confirmed at the second PINBs as malignant tumors, respectively.
  • Benign neoplasms were confirmed in 8 cases, including fibrosis tissue in 6 lesions, bone tuberculosis in 1 and ovarian cyst in 1.
  • No hematoma, nerve damage, infection, and tumor transplantation in pelvic cavity developed after the PINB procedure.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Computer-Assisted / methods. Feasibility Studies. Female. Fibrosis / pathology. Fibrosis / radiography. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Tomography, X-Ray Computed. Uterine Neoplasms / pathology. Uterine Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021836.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


45. Hsuan CF, Tseng WK, Yang CH, Lee TL, Hu PY, Wu CC: Primary myxosarcoma of the right inferior pulmonary vein presenting clinically as benign left atrial myxoma with a concurrent right lower lung tumor. Circ J; 2009 Aug;73(8):1547-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary myxosarcoma of the right inferior pulmonary vein presenting clinically as benign left atrial myxoma with a concurrent right lower lung tumor.
  • Although myxomas are the most common intracavitary tumor of the left atrium, some findings should alert the clinician to the probability of malignancy.
  • She was preoperatively diagnosed as left atrial myxoma with a concurrent right lower lung tumor.
  • [MeSH-major] Lung Neoplasms / complications. Myxoma / diagnosis. Myxosarcoma / complications. Myxosarcoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Heart Atria / pathology. Humans. Pulmonary Veins / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139592.001).
  • [ISSN] 1347-4820
  • [Journal-full-title] Circulation journal : official journal of the Japanese Circulation Society
  • [ISO-abbreviation] Circ. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Fainstein Day P, Frohman L, Garcia Rivello H, Reubi JC, Sevlever G, Glerean M, Fernandez Gianotti T, Pietrani M, Rabadan A, Racioppi S, Bidlingmaier M: Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary; 2007;10(3):311-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
  • Although clinical improvement is common after treatment with somatostatin (SMS) analogs, the biochemical response and tumor size of the growth hormone-releasing hormone (GHRH)-producing tumor and its metastases are less predictable.
  • He had undergone lung surgery in 1987 for a "benign" carcinoid tumor.
  • Methods Measurement of circulating GHRH levels by fluorescence immunoassay levels and immunohistochemical study of the primary lung tumor and metastatic tissue with anti-GHRH and anti-somatostatin receptor type 2 (sst2A) antibodies.
  • Pathological study of liver and bone biopsy material and lung tissue removed 19 years earlier was consistent with an atypical carcinoid producing GHRH and exhibiting sst2A receptor expression.
  • No changes were observed in lung and liver metastases.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / secondary. Bronchial Neoplasms / secretion. Carcinoid Tumor / secondary. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Hormones, Ectopic / secretion. Human Growth Hormone / secretion. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):395-9 [2899089.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):906-13 [3093533.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Endokrynol Pol. 2006 Jan-Feb;57(1):32-6 [16575760.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):819-25 [2582209.001]
  • [Cites] Endocrinol Metab Clin North Am. 1991 Sep;20(3):507-18 [1935918.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jun;34(6):463-7 [1653654.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1642-51 [16327437.001]
  • [Cites] Neurochirurgia (Stuttg). 1992 Sep;35(5):160-2 [1436366.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Endocrinology. 1989 Aug;125(2):801-9 [2502376.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2605-13 [15495181.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):675-86 [9662588.001]
  • [Cites] J Laryngol Otol. 2005 May;119(5):405-8 [15949110.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10 [8784011.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31 [15272918.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • (PMID = 17373589.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Hormones, Ectopic; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


47. Miwa K, Taniguchi Y, Adachi Y, Haruki T, Nakamura H: [Huge mediastinal mature teratoma with combined resection of adjacent structures; report of a case]. Kyobu Geka; 2006 Nov;59(12):1115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 64-year-old woman with an anterior mediastinal tumor on a chest computed tomography (CT) before operation of uterine cancer.
  • After the radical surgery and a chemotherapy for uterine cancer, surgical resection of mediastinal tumor was performed in July 2005 because of gradually progression in tumor size.
  • Under the median sternotomy, the tumor revealed intensive adhesion to the right lung and the left brachiocephalic vein.
  • We performed a complete resection of the tumor with combined resection of adherent parts of them.
  • The tumor was 9 x 8 cm in size, containing with yellow cream-like fluid and hair.
  • Histologically, the tumor was diagnosed as a mature teratoma with the tissue of bone, digestive tract epithelium, bronchial epithelium and so on.
  • In benign teratoma, it is not rare to perforate to the adjacent structures.
  • [MeSH-major] Brachiocephalic Veins / surgery. Lung Diseases / surgery. Mediastinal Neoplasms / surgery. Teratoma / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17094553.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is an asbestos-related tumour.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


49. Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA, Horst PK, Jain S, Cekic V, Kirman I, Whelan RL: Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg; 2006 Nov;244(5):792-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis that is necessary for wound healing and also promotes tumor growth.
  • It is anticipated that plasma levels would increase after major surgery and that such elevations may facilitate tumor growth.
  • METHODS: Colorectal resection for cancer (n = 139) or benign pathology (n = 48) and gastric bypass for morbid obesity (n = 40) were assessed.
  • RESULTS: The mean preoperative VEGF level of the cancer patients was significantly higher than baseline level of benign colon patients.
  • CONCLUSION: As a group colon cancer patients prior to surgery have significantly higher mean VEGF levels than patients without tumors.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Br J Surg. 2001 Aug;88(8):1105-9 [11488797.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):417-23 [11875709.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):36-9 [11961601.001]
  • [Cites] Surgery. 2002 May;131(5):548-55 [12019409.001]
  • [Cites] Transfusion. 1999 Oct;39(10):1078-83 [10532601.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):874-9 [10543260.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):333-8 [10671682.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3147-52 [10955796.001]
  • [Cites] World J Surg. 2000 Oct;24(10):1264-70 [11071473.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1162-9 [11984655.001]
  • [Cites] Surgery. 2002 Aug;132(2):186-92 [12219010.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Nov;283(5):L1133-42 [12376368.001]
  • [Cites] Gastric Cancer. 2002;5(3):137-41 [12378339.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):271-4 [12807238.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Oct;27(10):1187-95 [14513066.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4340-51 [14530359.001]
  • [Cites] J Surg Res. 2003 Nov;115(1):113-20 [14572781.001]
  • [Cites] Cytokine. 2004 Jan 21;25(2):68-72 [14693162.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):270-8 [14716760.001]
  • [Cites] Surgery. 1986 Aug;100(2):273-7 [3738755.001]
  • [Cites] Cancer Detect Prev. 1988;12(1-6):421-9 [3263198.001]
  • [Cites] Nihon Geka Gakkai Zasshi. 1989 Aug;90(8):1245-50 [2811843.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Arch Surg. 1995 Jun;130(6):649-53 [7763175.001]
  • [Cites] Nat Biotechnol. 1997 Jun;15(6):510 [9181567.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):956-64 [9528841.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):564-9 [9593237.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1279-85 [9607588.001]
  • [Cites] Clin Sci (Lond). 1998 Apr;94(4):395-404 [9640345.001]
  • [Cites] Surg Endosc. 1998 Aug;12(8):1035-8 [9685537.001]
  • [Cites] Surgery. 1998 Sep;124(3):516-25 [9736904.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1419-24 [9769380.001]
  • [Cites] Br J Surg. 1998 Oct;85(10):1439-42 [9782033.001]
  • [Cites] Chest. 1998 Dec;114(6):1668-75 [9872204.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Surg Endosc. 1999 Mar;13(3):233-5 [10064753.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):487-91 [10100697.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):477-81 [10215047.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4804-7 [10519388.001]
  • [Cites] Surg Endosc. 2005 Jan;19(1):55-9 [15531967.001]
  • [Cites] Int J Obes (Lond). 2005 Nov;29(11):1308-14 [15953938.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [CommentIn] Ann Surg. 2007 Jul;246(1):160-1; author reply 161 [17592305.001]
  • (PMID = 17060773.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1856599
  •  go-up   go-down


50. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer.
  • Clinical significance of serum DKK1 in lung cancer remains to be determined.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Application of both DKK1 and cytokeratin 19 fragment increased sensitivity, correctly identifying 89.6% of the non-small cell lung cancer patients as positive.
  • The use of both DKK1 and neuron-specific enolase increased sensitivity to detect small cell lung cancer to 86.2%.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • CONCLUSIONS: DKK1 was preferentially expressed in lung cancer.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


51. Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K, Yamamoto H, Tsuchiya H: Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer; 2007 Jun 15;109(12):2532-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chondrosarcoma, the second most frequent primary malignant bone tumor, is classified into 3 grades according to histologic criteria of malignancy.
  • However, a low-grade lesion can be difficult to distinguish from a benign enchondroma, whereas some histologically low-grade lesions may carry a poor prognosis.
  • Associations of these molecules with histology and clinical behavior of tumors were analyzed.
  • High expression of esRAGE in grade 1 chondrosarcoma was associated with subsequent recurrence (P = .0013), lung metastasis (P = .0071), and poor survival (P < .001).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / metabolism. Chondroma / metabolism. Chondrosarcoma / metabolism. Receptors, Immunologic / metabolism

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17497647.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / Glycosylation End Products, Advanced; 0 / HMGB1 Protein; 0 / Receptors, Immunologic
  •  go-up   go-down


52. Kesler KA, Wilson JL, Cosgrove JA, Brooks JA, Messiha A, Fineberg NS, Einhorn LH, Brown JW: Surgical salvage therapy for malignant intrathoracic metastases from nonseminomatous germ cell cancer of testicular origin: analysis of a single-institution experience. J Thorac Cardiovasc Surg; 2005 Aug;130(2):408-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cisplatin-based chemotherapy followed by surgical extirpation of residual benign disease represents the usual sequence of curative therapy for metastatic nonseminomatous germ cell cancer of testicular origin.
  • Occasionally, residual disease is malignant in the form of either a persistent nonseminomatous germ cell cancer tumor or degeneration into non-germ cell cancer.
  • Surgical pathology demonstrated 84 patients with persistent nonseminomatous germ cell cancer tumors, 38 with degeneration into non-germ cell cancer, and 12 with both malignant pathologic categories.
  • CONCLUSIONS: Salvage thoracic surgery to remove malignant metastases from nonseminomatous germ cell cancer tumors of testicular origin can result in long-term survival in select patients.
  • [MeSH-major] Lung Neoplasms / therapy. Mediastinal Neoplasms / therapy. Neoplasms, Germ Cell and Embryonal / therapy. Testicular Neoplasms / therapy. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome


53. Glaab R, Turina M, Achermann E, Maurer R, Went P, Schöb O: [Alveolar adenoma--a rare pulmonary mass: case report and review of the literature]. Zentralbl Chir; 2009 Sep;134(5):478-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive histology following thoracoscopic wedge resection showed the distinctive findings of an alveolar adenoma, a very rare benign tumour of the lung of unknown histogenesis.
  • Its histological features, the benign proliferation of alveolar epithelium and septal mesenchyme, allow for its distinction from other benign lesions of the lung.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Hemoptysis / etiology. Humans. Lung / pathology. Male. Middle Aged. Phlebography. Pneumonectomy. Thoracoscopy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag Stuttgart-New York.
  • (PMID = 19757349.001).
  • [ISSN] 1438-9592
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 5
  •  go-up   go-down


54. Wang WB, Cui YG, Yao SY: [Message RNA expression of LUNX, CK19 and CEA genes in NSCLC with micrometastasis in lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2008 Feb;30(2):121-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the correlation of mRNA expression level of three cancer-associated genes-LUNX mRNA, CK19 mRNA and CEA mRNA with metastasis in lymph nodes and histopathological staging in non-small cell lung cancer (NSCLC).
  • METHODS: Fifty-six tumor tissue samples and 103 regional lymph node samples were obtained from 56 patients with NSCLC, and another 35 lymph node samples as control from 15 patients with benign pulmonary diseases.
  • RESULTS: mRNA expression of LUNX, CK19 and CEA genes in the regional lymph nodes of NSCLC was significantly higher than that in those of benign lung diseases (P < 0.05).
  • No significant correlation was found between positive mRNA expression of LUNX mRNA and CK19 mRNA in the lymph nodes and histopathologic type of lung cancer (P > 0.05).
  • CONCLUSION: LUNX mRNA and CK19 mRNA may serve as a molecular marker for detection of lymph node micrometastasis in patient with non-small cell lung cancer, but LUNX mRNA is superior to CK19 mRNA in both sensitivity and specificity.
  • [MeSH-major] Carcinoembryonic Antigen / metabolism. Glycoproteins / metabolism. Keratin-19 / metabolism. Lung Neoplasms / metabolism. Lymph Nodes / metabolism. Phosphoproteins / metabolism
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646695.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Carcinoembryonic Antigen; 0 / Glycoproteins; 0 / Keratin-19; 0 / Phosphoproteins; 0 / RNA, Messenger
  •  go-up   go-down


55. Yamamoto Y, Nishiyama Y, Ishikawa S, Gotoh M, Bandoh S, Kanaji N, Asakura M, Ohkawa M: 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose. J Comput Assist Tomogr; 2008 May-Jun;32(3):432-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.
  • OBJECTIVE: The purpose of this study was to evaluate the accuracy of 3'-deoxy-3'-F-fluorothymidine (FLT) positron emission tomography (PET) for detection of lung tumor in comparison with 2-deoxy-2-F-fluoro-D-glucose (FDG) PET.
  • METHODS: Fifty-four patients with newly diagnosed pulmonary nodules on chest computed tomographic (CT) scan suggestive of a malignant tumor were examined with both FLT and FDG PET.
  • The intensity of uptake in lung tumors was scored.
  • RESULTS: Thirty-six patients were found to have lung cancer; and 18, benign lesions.
  • Using visual analysis, the sensitivity of FLT PET for detection of lung cancer was 83%; the specificity, 83%; and the accuracy, 83%.
  • The uptake of FLT in lung cancer was significantly lower than that of FDG.
  • CONCLUSIONS: These preliminary results indicate that FLT PET may be specific for malignant tumors although uptake of FLT in lung cancer was significantly lower than that of FDG.
  • [MeSH-major] Dideoxynucleosides. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520552.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N: Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. Proc Natl Acad Sci U S A; 2007 Jun 19;104(25):10625-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF-A monoclonal antibodies, in combination with chemotherapy, result in a survival benefit in patients with metastatic colorectal and non-small cell lung cancer, but little is known regarding the impact of anti-VEGF-A therapy on benign or premalignant tumors.
  • To investigate whether tumor growth in Apc+/min mice is mediated by VEGF-A-dependent angiogenesis, we used two independent approaches to inhibit VEGF-A: monotherapy with a monoclonal antibody (Mab) targeting VEGF-A and genetic deletion of VEGF-A selectively in intestinal epithelial cells.
  • Deletion of VEGF-A in intestinal epithelial cells of Apc+/min mice yielded a significant inhibition of tumor growth, albeit of lesser magnitude than that resulting from Mab G6-31 administration.
  • These results establish that inhibition of VEGF-A signaling is sufficient for tumor growth cessation and confers a long-term survival benefit in an intestinal adenoma model.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):316-25 [16507828.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Cancer Lett. 2002 Jan 25;175(2):157-63 [11741743.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Dev Dyn. 2002 May;224(1):90-102 [11984877.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):391-400 [12750232.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1445-52 [12778076.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Curr Biol. 2003 Sep 30;13(19):1721-7 [14521839.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] J Exp Med. 1972 Aug 1;136(2):261-76 [5043412.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Dec;82(24):8488-92 [3909146.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Development. 1992 Jul;115(3):717-28 [1425351.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2556-60 [8653697.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4267-73 [9331087.001]
  • [Cites] Prostate. 1998 Apr 1;35(1):1-10 [9537593.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):51-8 [9934849.001]
  • [Cites] Development. 1999 Mar;126(6):1149-59 [10021335.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4389-400 [15899831.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):549-60 [16336962.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1710-7 [16685275.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2133-9 [16782971.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3478-83 [17360669.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • (PMID = 17553957.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC1888576
  •  go-up   go-down


57. Nadelman CM, Leslie KO, Fishbein MC: "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases. Arch Pathol Lab Med; 2006 Sep;130(9):1349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases.
  • Adenomyoepitheliomas of the breast are rare tumors composed of a proliferation of 2 cell populations.
  • For the most part, they are considered to be benign, but they locally recur.
  • Those neoplasms that metastasize are deemed to have come from a histologically malignant primary tumor.
  • Herein, we describe 2 cases of metastases of histologically "benign" adenomyoepitheliomas of the breast to the lung.
  • Establishing the diagnosis, determining optimal therapy, and predicting outcome are problematic because of the rarity of this entity.
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948523.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Kurli M, Reddy S, Tena LB, Pavlick AC, Finger PT: Whole body positron emission tomography/computed tomography staging of metastatic choroidal melanoma. Am J Ophthalmol; 2005 Aug;140(2):193-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two were imaged before treatment of their primary tumor.
  • The mean time from initial diagnosis to metastasis was 47 months (range 0 to 154).
  • The most common sites for metastases were the liver (100%), bone (50%), lung (25%), lymph nodes (25%), and subcutaneous tissue (25%).
  • PET/computed tomography imaging also detected benign lesions of the bone and lymph nodes in three patients (15%).
  • [MeSH-minor] Aged. Aged, 80 and over. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15992753.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


59. Peng HQ, Greenwald BD, Tavora FR, Kling E, Darwin P, Rodgers WH, Berry A: Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas. Diagn Cytopathol; 2008 May;36(5):290-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of performance of EUS-FNA in preoperative lymph node staging of cancers of esophagus, lung, and pancreas.
  • We reviewed the cytologic and histologic diagnoses and EUS report of 77 consecutive patients who had undergone EUS-FNA preoperative staging for esophageal, lung, and pancreatic cancers at our institution.
  • We compared cytologically malignant and benign lymph node groups with eight EUS parameters including the total number of lymph nodes found by EUS, the shape, margin, long axis, short axis, echogenicity, location of the lymph node, and EUS tumor staging.
  • Lymph nodes found in an abdominal location in esophageal and lung cancer are likely malignant.
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Lymphatic Metastasis / pathology. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418852.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Priebe-Richter C, Ivanyi P, Buer J, Länger F, Lotz J, Hertenstein B, Ganser A, Franzke A: Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. Eur J Haematol; 2005 Jul;75(1):68-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease.
  • Inflammatory myofibroblastic tumor (IMT) is an uncommon cause of solitary or multifocal lung nodules and can also be rarely found in various other extrapulmonary sites.
  • Although this pseudotumor is benign, it can be locally very aggressive.
  • Here, we report a case of inflammatory pseudotumor of the lung secondary to invasive pulmonary aspergillosis in a patient with chronic graft-vs.-host disease.
  • [MeSH-major] Aspergillosis / pathology. Graft vs Host Disease. Lung Diseases, Fungal / pathology. Plasma Cell Granuloma, Pulmonary / pathology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Blackwell Munksgaard 2005.
  • (PMID = 15946314.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Steroids
  •  go-up   go-down


61. Roeder F, Friedrich J, Timke C, Kappes J, Huber P, Krempien R, Debus J, Bischof M: Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer. Strahlenther Onkol; 2010 Mar;186(3):149-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of patient-related factors and dose-volume histogram parameters with the onset of radiation pneumonitis in patients with small cell lung cancer.
  • PURPOSE: To analyze the association of patient- and treatment-related factors with the onset of radiation pneumonitis in a homogeneously treated cohort of patients suffering from small cell lung cancer (SCLC).
  • Patient- (age, gender, smoking history, performance status, tumor localization, benign lung disease) and treatment-related parameters (V(10)-V(40), mean lung dose [MLD]) were analyzed using χ(2)-tests for categorical parameters and logistic regression for continuous variables.
  • Considering treatment-related parameters, a significant correlation of V(30) in regard to total lung and V(40) in regard to ipsilateral, contralateral and total lung to the risk of pneumonitis was found.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / radiotherapy. Radiation Pneumonitis / epidemiology. Radiotherapy, Conformal / statistics & numerical data. Small Cell Lung Carcinoma / epidemiology. Small Cell Lung Carcinoma / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2008 Feb;184(2):61-6 [18259696.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:3-4 [19685024.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):231-4 [19370425.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):329-39 [12243805.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):175-81 [15110451.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1208-9; author reply 1209 [12829167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):455-60 [7673033.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1065-70 [8648358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1399-407 [16997503.001]
  • [Cites] Strahlenther Onkol. 2007 Apr;183(4):215-7 [17406804.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):323-9 [10487552.001]
  • [Cites] Strahlenther Onkol. 2009 Aug;185 Suppl 2:21-2 [19685030.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):650-9 [11597805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):5-24 [15963660.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):679-84 [18040612.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):112-24 [16618575.001]
  • [Cites] Strahlenther Onkol. 2007 Oct;183(10):545-51 [17896085.001]
  • [Cites] Strahlenther Onkol. 2003 Aug;179(8):548-56 [14509954.001]
  • [Cites] Strahlenther Onkol. 2009 Jan;185(1):27-33 [19224144.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):296-301 [18535804.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):524-30 [1310160.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3201-6 [12874270.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1075-86 [16647222.001]
  • [Cites] Strahlenther Onkol. 2008 Apr;184(4):193-7 [18398583.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):127-38 [15110445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):469-78 [9806503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):106-13 [12694828.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):605-9 [19016020.001]
  • [Cites] Ann Oncol. 1995 Sep;6(7):693-7 [8664191.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):289-95 [18535803.001]
  • (PMID = 20165822.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • Initial chemotherapies failed to control the tumor.
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


63. Harrison-Phipps KM, Nichols FC, Schleck CD, Deschamps C, Cassivi SD, Schipper PH, Allen MS, Wigle DA, Pairolero PC: Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis. J Thorac Cardiovasc Surg; 2009 Jul;138(1):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis.
  • OBJECTIVE: We sought to define the long-term outcome of surgically treated solitary fibrous tumors of the pleura.
  • Tumors were polypoid in 57 patients, sessile in 20 patients, and intrapulmonary in 7 patients.
  • Histopathology was benign in 73 and malignant in 11 patients.
  • Nine (82%) patient with malignant tumors and 37 (54%) patients with benign tumors were symptomatic (P = .11).
  • The median tumor diameters for malignant and benign tumors were 12.0 and 4.5 cm, respectively (P = .001).
  • Median survival for patients with benign and malignant tumors was 284 and 55 months, respectively, and 5-year survival was 88.9% and 45.5%, respectively (P = .0005).
  • Eight (9.5%) patients had recurrent solitary fibrous tumors of the pleura.
  • Recurrences were malignant in 6 and benign in 2 patients.
  • CONCLUSION: Resection of benign solitary fibrous tumors of the pleura carries an excellent prognosis.
  • Larger tumors are more likely to be malignant.
  • Both benign and malignant tumors can recur.
  • Although prolonged survival after resection of malignant tumors is possible, recurrence is common.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Ann Thorac Surg. 1999 May;67(5):1456-9 [10355431.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] J Thorac Surg. 1952 Sep;24(3):213-30 [13000916.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):197-201 [16354315.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • (PMID = 19577049.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217187; NLM/ PMC2930758
  •  go-up   go-down


64. Fang FC, Lee SC, Hsu HH, Peng YJ, Chang H, Cheng YL: Inflammatory myofibroblastic tumor of the lung: unusual presentation. Lung; 2008 May-Jun;186(3):191-193
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor of the lung: unusual presentation.
  • Inflammatory myofibroblastic tumor (IMT) of the lung is a rare entity considered to be a benign neoplastic lesion.
  • Because of its variable cellular composition, it seldom allows diagnosis preoperatively either through transthoracic fine-needle aspiration or bronchoscopic biopsy.
  • In this report we describe a unique occurrence of a rarely described large inflammatory myofibroblastic tumor of the lung that mimics a posterior mediastinal tumor in a 45-year-old female, detailing clinical presentation, imaging, and management.
  • [MeSH-major] Plasma Cell Granuloma, Pulmonary / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Middle Aged. Pneumonectomy. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1477-82 [8633962.001]
  • [Cites] Korean J Intern Med. 2002 Dec;17(4):252-8 [12647641.001]
  • [Cites] Cancer. 1986 Jun 1;57(11):2127-9 [3697912.001]
  • [Cites] Radiology. 1998 Feb;206(2):511-8 [9457206.001]
  • [Cites] Ann Thorac Surg. 1999 Apr;67(4):933-6 [10320231.001]
  • [Cites] J Pediatr Surg. 1991 Sep;26(9):1064-6 [1941485.001]
  • [Cites] J Comput Assist Tomogr. 1988 Jul-Aug;12 (4):653-5 [3392271.001]
  • [Cites] Ann Thorac Surg. 2003 Aug;76(2):601-3 [12902113.001]
  • [Cites] J Pathol. 2000 Nov;192(3):277-9 [11054708.001]
  • (PMID = 18297338.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Ayadi-Kaddour A, Ben Slama S, Braham E, Abid L, Ismail O, Smati B, Djilani H, El Mezni F: [Desmoplastic fibroma of the rib: two case reports]. Ann Pathol; 2005 Oct;25(5):398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Le fibrome desmoplastique de la côte: à propos de deux observations.
  • Desmoplastic fibroma is a very rare primary tumor of bone, closely related to aggressive fibromatosis of soft tissue.
  • Although considered a benign lesion, it can be very aggressive locally and has a high rate of local recurrence after incomplete surgical excision.
  • Histological examination after surgical resection revealed that the tumor consisted of spindle cells with small, elongated nuclei in a background of numerous collagen fibers and infiltrating lamellar bone.
  • We also discuss histological differential diagnosis as well as clinical features and the radiological and pathologic findings of this rare disease.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Collagen / analysis. Diagnosis, Differential. Female. Fibroblasts / pathology. Humans. Lung / pathology. Lung / surgery. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local / surgery. Pneumonectomy. Thoracic Wall / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498294.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


66. Ludlow A, Yee KO, Lipman R, Bronson R, Weinreb P, Huang X, Sheppard D, Lawler J: Characterization of integrin beta6 and thrombospondin-1 double-null mice. J Cell Mol Med; 2005 Apr-Jun;9(2):421-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The double-null mice exhibited focal acute and organizing pneumonia that was more severe than the wild-type and single-null mice as well as a significantly higher incidence of inflammation in tissues other than the lung.
  • The TSP-1-null and beta6-null mice exhibited a five to eight-fold increase in granulocyte recruitment to the lung three days after exposure to lipopolysaccharide.
  • Furthermore, the beta6-null and double-null mice displayed a significant elevation in benign and malignant cancers.
  • They also indicate that alphavbeta6 functions as a tumor suppressor gene and that activation of TGFbeta by TSP-1 and alphavbeta6 contributes to normal tissue architecture and function.
  • [MeSH-minor] Alopecia / genetics. Animals. Cardiomyopathies / genetics. Cardiomyopathies / pathology. Crosses, Genetic. Epithelium / pathology. Female. Genital Diseases, Female / genetics. Genital Diseases, Female / pathology. Hyperplasia / genetics. Hyperplasia / pathology. Longevity / genetics. Lung Diseases / genetics. Lung Diseases / pathology. Male. Mice. Mice, Knockout. Mice, Mutant Strains. Neoplasms, Squamous Cell / genetics. Neoplasms, Squamous Cell / pathology. Phenotype. Pneumonia / genetics. Pneumonia / pathology. Stomach Diseases / genetics. Stomach Diseases / pathology. Transforming Growth Factor beta / metabolism

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963261.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86410; United States / NCI NIH HHS / CA / CA92644; United States / NHLBI NIH HHS / HL / HL53949; United States / NHLBI NIH HHS / HL / HL68003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Integrin beta Chains; 0 / Thrombospondin 1; 0 / Transforming Growth Factor beta; 0 / integrin beta6
  •  go-up   go-down


67. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


68. Meirelles GS, Ravizzini G, Moreira AL, Akhurst T: Primary pulmonary meningioma manifesting as a solitary pulmonary nodule with a false-positive PET scan. J Thorac Imaging; 2006 Aug;21(3):225-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lesions are usually benign, grow slowly, and have an excellent prognosis.
  • However, they can mimic any other pulmonary tumor, as the most common presentation is as a solitary pulmonary nodule.
  • We report a case of a primary pulmonary meningioma manifesting as a solitary lung nodule with a very high metabolic activity on the positron emission tomography, mimicking a primary lung cancer.
  • [MeSH-major] False Positive Reactions. Lung Neoplasms / radionuclide imaging. Meningioma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16915069.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Revel MP, Merlin A, Peyrard S, Triki R, Couchon S, Chatellier G, Frija G: Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules. AJR Am J Roentgenol; 2006 Jul;187(1):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Software volumetric evaluation of doubling times for differentiating benign versus malignant pulmonary nodules.
  • OBJECTIVE: The purpose of our study was to evaluate the reliability of software-calculated doubling times for discerning malignant versus benign nodules.
  • MATERIALS AND METHODS: CT lung analysis volumetric software was used to retrospectively calculate the doubling times of 63 solid noncalcified nodules by comparing nodule volumes on baseline and follow-up CT scans obtained a median of 3.7 months apart.
  • A final diagnosis based on validated criteria was available for all 63 nodules.
  • Taking 500 days as the upper value for malignancies, we evaluated whether the software-calculated doubling times could be used to distinguish malignant from benign solid nodules.
  • We also examined whether the relative volume variation of benign nodules correlated with initial nodule size, interscan interval, or differences in contrast administration or exposure parameters between baseline and follow-up CT.
  • RESULTS: There were 52 benign and 11 malignant nodules.
  • Benign nodules had a median doubling time of 947 days and a mean relative volume variation of -4.4% (range, -50% to 38%).
  • No correlation was found between the relative volume variation of benign nodules and their initial size, the interscan interval, or differences in contrast administration or exposure parameters between the two CT examinations.
  • CONCLUSION: Software-calculated pulmonary nodule doubling times of more than 500 days have a 98% negative predictive value for the diagnosis of solid malignant pulmonary nodules.
  • [MeSH-major] Image Processing, Computer-Assisted. Lung / radiography. Lung Diseases / radiography. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Imaging, Three-Dimensional. Lung Neoplasms. Male. Middle Aged. Software. Tumor Burden

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794167.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Adachi Y, Horie Y, Kitamura Y, Nakamura H, Taniguchi Y, Miwa K, Fujioka S, Nishimura M, Hayashi K: CD1a expression in PEComas. Pathol Int; 2008 Mar;58(3):169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the World Health Organization classification, neoplasms with perivascular epithelioid cell differentiation (PEComas) are mesenchymal tumors composed of histologically and immunohistochemically distinctive PEC.
  • Recently the authors reported that benign clear cell sugar tumor of the lung, one of the PEComas, expressed CD1a.
  • Nineteen PEComas were obtained, which included angiomyolipoma of the kidney or liver, lymphangiomyomatosis of the uterus or lung and clear cell sugar tumor of the lung.
  • Eighteen tumors had alpha-SMA and HMB-45 expression and 16 had melan A expression.
  • In contrast, all 19 tumors had CD1a expression.
  • [MeSH-major] Antigens, CD1 / metabolism. Biomarkers, Tumor / metabolism. Epithelioid Cells / metabolism. Neoplasms, Connective and Soft Tissue / metabolism

  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251780.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Biomarkers, Tumor; 0 / CD1a antigen
  •  go-up   go-down


76. Bitterlich N, Muley T, Schneider J: Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation. Anticancer Res; 2010 May;30(5):1661-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
  • The diagnosis of non-small cell lung cancer (NSCLC) by using tumour markers needs to be improved and standardised in order to compare marker profiles from different centres.
  • A centre-independent tool based on receiver operating characteristics (ROC) curves instead of cut-off-based approaches for NSCLC diagnosis was established.
  • Carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were measured in 326 NSCLC patients and 160 patients with benign lung diseases (Heidelberg, HD) and compared to 158 NSCLC patients and 128 controls from an occupational medicine high-risk cohort (Giessen, GI).
  • The cohorts differed in tumour-stages, marker cut-offs and therefore in sensitivity for NSCLC detection.
  • The diagnosis of NSCLC based on ROC curves eliminate centre-specific differences.
  • Classification methods lead to an improvement in NSCLC diagnosis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / biosynthesis. Cohort Studies. Female. Humans. Keratin-19 / biosynthesis. Male. Middle Aged. Models, Statistical. ROC Curve. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592358.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19
  •  go-up   go-down


77. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • These usually metastasize to the lung, pleura, bone, and liver.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


78. Juretzka MM, Crawford CL, Lee C, Wilton A, Schuman S, Chi DS, Sonoda Y, Barakat RR, Abu-Rustum NR: Laparoscopic findings during adnexal surgery in women with a history of nongynecologic malignancy. Gynecol Oncol; 2006 May;101(2):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prior cancer history included breast (202, 77.1%), lymphoma/leukemia (16, 6.1%), colorectal (8, 3.0%), lung (7, 2.7%), multiple myeloma (5, 1.9%), head/neck (5, 1.9%), genitourinary (5, 1.9%), upper gastrointestinal (4, 1.5%), and other (10, 3.8%).
  • Median tumor diameter and CA-125 were significantly higher in women found to have a malignancy (4.7 vs. 3.7 cm, and 35 vs. 14 U/mL, respectively).
  • Twenty-one of 49 (42.9%) patients with malignancy were converted to laparotomy compared with 13/213 (6.1%) when benign disease was noted (P < 0.001).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16360202.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Granberg D, Wilander E, Oberg K: Expression of tyrosine kinase receptors in lung carcinoids. Tumour Biol; 2006;27(3):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of tyrosine kinase receptors in lung carcinoids.
  • OBJECTIVES: Typical lung carcinoids are usually relatively benign tumors, but distant metastases are seen in up to 12% of the patients.
  • In contrast, atypical carcinoids are more aggressive tumors, displaying metastases in up to 70%.
  • The current treatment of metastatic lung carcinoids is discouraging.
  • New therapies, such as inhibitors of the tyrosine kinase receptor family c-kit, platelet-derived growth factor receptors (PDGFR) alpha and beta and epidermal growth factor receptor (EGFR) have shown promising results in other malignancies and might be of value in malignant lung carcinoids.
  • PATIENTS AND METHODS: Tumor tissue from 51 patients with typical lung carcinoids were immunostained with polyclonal antibodies against c-kit, PDGFRalpha, PDGFRbeta and EGFR.
  • RESULTS: Twelve of the tumors stained positive for c-kit, 44 expressed PDGFRalpha, 30 showed positive immunoreactivity for PDGFRbeta and 26 were EGFR immunoreactive.
  • Among the 17 patients with distant metastases, 5 tumors expressed c-kit, 12 were PDGFRalpha immunoreactive, 9 stained positive for PDGFRbeta, and 7 showed positive immunoreactivity for EGFR.
  • CONCLUSIONS: Tyrosine kinase receptors such as c-kit, PDGFRalpha, PDGFRbeta and EGFR are expressed in a significant number of patients with metastatic lung carcinoids.
  • [MeSH-major] Carcinoid Tumor / diagnosis. Lung Neoplasms / diagnosis. Receptor Protein-Tyrosine Kinases / analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16612146.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


80. Arif S, Ganesan R, Spooner D: Intravascular leiomyomatosis and benign metastasizing leiomyoma: an unusual case. Int J Gynecol Cancer; 2006 May-Jun;16(3):1448-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular leiomyomatosis and benign metastasizing leiomyoma: an unusual case.
  • Benign metastasizing leiomyoma (BML) and intravascular leiomyomatosis (IVL) are rare variants of uterine leiomyomas.
  • The remaining tumor was treated with a gonadotrophin-releasing hormone agonist, resulting in significant reductions in tumor size.
  • It was concluded that the lesions in the lungs were an example of BML arising from the initial diagnosis of uterine leiomyoma, and the caval lesion was an IVL.
  • Long-term follow-up is recommended, and familiarity with rare forms of benign smooth muscle uterine tumors is essential in avoiding misdiagnosis and overtreatment.
  • [MeSH-major] Leiomyoma / diagnosis. Leiomyomatosis / diagnosis. Uterine Neoplasms / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Magnetic Resonance Imaging

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803546.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res; 2008 May;18(5):549-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A microRNA expression screen was performed analyzing 157 different microRNAs in laser-microdissected tissues from benign melanocytic nevi (n = 10) and primary malignant melanomas (n = 10), using quantitative real-time PCR.
  • Members of the let-7 family of microRNAs were significantly downregulated in primary melanomas as compared with benign nevi, suggestive for a possible role of these molecules as tumor suppressors in malignant melanoma.
  • Interestingly, similar findings had been described for lung and colon cancer.
  • Taken together, these findings not only point to new regulatory mechanisms of early melanoma development, but also may open avenues for future targeted therapies of this tumor.


82. Greiner B, Schulz C, Pfeifer M, Heiss P, Völk M, Feuerbach S, Hamer OW: [A 74-year-old female patient with histologically proven carcinoid of the lungs and pulmonary mosaic pattern]. Radiologe; 2009 Jun;49(6):538-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] 74-jährige Patientin mit histologisch gesichertem Karzinoid der Lunge und pulmonalem Mosaikmuster.
  • DIPNECH can be complicated by obliterative bronchiolitis and is presumably often misdiagnosed because the clinical symptoms are unspecific, the entity is relatively unknown and high-resolution computed tomography (HRCT) in inspiration and expiration is necessary for the diagnosis.
  • DIPNECH is thought to be a precursor of tumorlets and carcinoids and usually runs a benign course.
  • The diagnosis is confirmed by histology.
  • [MeSH-major] Carcinoid Tumor / diagnostic imaging. Carcinoid Tumor / pathology. Lung / diagnostic imaging. Lung / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Radiography

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2007 Mar;62(3):248-52 [17099078.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):839-44 [16784983.001]
  • [Cites] Am Rev Respir Dis. 1993 Nov;148(5):1166-8 [8239148.001]
  • [Cites] Chest. 2007 Jun;131(6):1635-43 [17400673.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):180-4 [11884770.001]
  • [Cites] Radiographics. 1999 May-Jun;19(3):707-36 [10336200.001]
  • [Cites] Am J Surg Pathol. 1995 Jun;19(6):653-8 [7755151.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jun;168(6):1561-2 [9168724.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1285-8 [1406819.001]
  • (PMID = 19034406.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Schlimper C, Sommer T, Flacke S, Wolff M, Schild H, Kreft B: [Radiologic features of inflammatory pseudotumors]. Rofo; 2005 Nov;177(11):1506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory pseudotumor is a rare benign tumor entity.
  • Because inflammatory pseudotumors mimic malignant tumors both clinically and radiologically, the radiologist should be familiar with this entity.
  • Inflammatory pseudotumor most commonly involves the lung and the orbit, but it has been reported to occur in nearly every site in the body.
  • For making a definite diagnosis a biopsy is often essential.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Heart Diseases / diagnosis. Heart Diseases / radiography. Humans. Liver Diseases / diagnosis. Liver Diseases / radiography. Magnetic Resonance Imaging. Male. Orbital Pseudotumor / diagnosis. Orbital Pseudotumor / radiography. Plasma Cell Granuloma, Pulmonary / diagnosis. Plasma Cell Granuloma, Pulmonary / radiography. Radiography, Abdominal. Radiography, Thoracic. Splenic Diseases / diagnosis. Splenic Diseases / radiography. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302131.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 54
  •  go-up   go-down


84. Kim HK, Choi YS, Kim K, Shim YM, Jeong SY, Lee KS, Kwon OJ, Kim J: Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer. J Thorac Oncol; 2009 Oct;4(10):1242-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of ground-glass opacity lesions detected in patients with otherwise operable non-small cell lung cancer.
  • INTRODUCTION: When pure ground-glass opacity (GGO) lesions are detected in patients with otherwise operable non-small cell lung cancer, it is controversial whether to resect them simultaneously with the primary tumor or not.
  • METHODS: We retrospectively reviewed radiologic features and pathologic diagnoses of pure GGO lesions detected in otherwise operable non-small cell lung cancer.
  • Four of the eight lesions that were simultaneously resected at surgery for the primary tumor turned out to be malignant.
  • We tried to predict whether a lesion is benign or malignant based on its size.
  • CONCLUSIONS: When a pure GGO is detected in otherwise operable lung cancer, it should be resected to rule out the possibility of malignancy if the size is greater than 8 mm.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / surgery. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adenocarcinoma, Bronchiolo-Alveolar / radiography. Adenocarcinoma, Bronchiolo-Alveolar / surgery. Adult. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiography. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiography, Interventional. Retrospective Studies. Sensitivity and Specificity. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687762.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • However, one patient with rectal carcinoma died of lung cancer during the follow-up period.
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Wu YJ, Hao YH, Wu WC, Wu YM: [Value of auto-fluorescence spectrum combined with tumor markers in diagnosis of lung cancer]. Guang Pu Xue Yu Guang Pu Fen Xi; 2009 Oct;29(10):2787-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of auto-fluorescence spectrum combined with tumor markers in diagnosis of lung cancer].
  • To improve the diagnostic efficiency of cancer, serum fluorescence spectrum combined with tumor marker groups was proved more powerful, especially when used with mathematical evaluation model, that is, artificial neural network (ANN) modeling.
  • ANN modeling is very suitable for the discrimination of lung cancer.
  • In the present paper, serum fluorescence spectrum was applied to study the difference among normal, benign and malignant groups and develop the relevant method of determination.
  • On the other hand, combined with tumor markers, CEA, NSE, SCC-Ag, CYFRA21-1 and p16 methylation, artificial neural network and Fisher linear discriminatory analysis were used to develop the prediction models of diagnosis of lung cancer, and compared by ROC.
  • It was shown that the result of the fluorescence spectrum combined with tumor markers based on ANN model is superior to that of the fluorescence spectrum ANN model.
  • [MeSH-major] Biomarkers, Tumor. Neural Networks (Computer)
  • [MeSH-minor] Fluorescence. Humans. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038061.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Wei EX, Anga AA, Martin SS, Jackson JG, Nordberg ML, Herrera GA, Turbat-Herrera EA: EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens. Mod Pathol; 2007 Sep;20(9):905-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimens.
  • Lung cancer evolves in a multistep process, and its early detection portends a better prognosis.
  • Bronchial washings/brushings and fine-needle aspirations are often used as early screening and cytological diagnosis of lung cancer.
  • Epidermal growth factor receptor (EGFR) is a transmembrane receptor overexpressed in high percentage lung cancers, and contributes to tumor growth.
  • Assessing EGFR expression levels by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) may provide critical information of tumor marker abnormalities, assist in the cytological diagnosis, and stratify patients for EGFR inhibitor therapy.
  • Fifty patients with bronchial washings/brushings or fine-needle aspiration specimens, and corresponding histologically confirmed lung biopsies, were studied for EGFR expression with FISH and IHC.
  • The benign or reactive cytology specimens confirmed by biopsies had high specificity by FISH (96%) and IHC (88%).
  • FISH and IHC analysis of EGFR, possibly along with other tumor markers, may be a useful ancillary tool to classify difficult cytology cases and inform clinicians arranging targeted chemotherapy.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Small Cell / diagnosis. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Lung Neoplasms / diagnosis. Receptor, Epidermal Growth Factor

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17643093.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


88. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung and intraabdominal organs are most frequently affected.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


89. Mackley HB, Videtic GM: Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park); 2006 Nov;20(12):1537-43; discussion 1544-5, 1549
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumors of the lung: a role for radiotherapy.
  • Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma.
  • [MeSH-major] Carcinoid Tumor / radiotherapy. Lung Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153907.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


90. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC: Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci; 2007 Feb;20(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer.
  • OBJECTIVE: To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis.
  • METHOD: Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals.
  • RESULTS: Profiling analysis demonstrated that an 11.6 kDa protein was significantly elevated in lung cancer patients, compared with the control groups (P < 0.001).
  • On the other hand, 11.6 kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls.
  • CONCLUSION: SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / blood. Serum Amyloid A Protein / analysis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peptides / blood. Protein Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458139.001).
  • [ISSN] 0895-3988
  • [Journal-full-title] Biomedical and environmental sciences : BES
  • [ISO-abbreviation] Biomed. Environ. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / Serum Amyloid A Protein
  •  go-up   go-down


91. Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M: Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience. Urology; 2007 Apr;69(4):637-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary tumor diagnosis or during follow-up.
  • The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma, breast cancer, gastric cancer, and melanoma.
  • Two patients had no history of a primary tumor.
  • The mean tumor size was 4.3 cm (range 1.5 to 9).
  • The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of benign pathologic features (35.3%).

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445640.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Gomard-Mennesson E, Isaac S, Freymond N, Guibert B, Pacheco Y, Devouassoux G: [Pulmonary metastases from Abrikossoff's tumour. Transformation capability of a benign granular cell tumour]. Rev Mal Respir; 2007 Sep;24(7):900-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary metastases from Abrikossoff's tumour. Transformation capability of a benign granular cell tumour].
  • [Transliterated title] Métastases pulmonaires d'une tumeur d'Abrikossoff. Transformation ou potentiel évolutif d'une tumeur bénigne à cellules granuleuses.
  • INTRODUCTION: Abrikossoff's tumour or granular cell tumour is usually benign involving multiple anatomical sites, most frequently the head, neck and airways.
  • CASE REPORT: We report the case of a mammary Abrikossoff's tumour, initially considered benign and treated solely by local surgery.
  • Seven years later the tumour was responsible for the development of sub-cutaneous and pulmonary metastases.
  • CONCLUSION: This original observation reports the case of a benign granular cell tumour that underwent malignant transformation after an interval of 7 years as indicated by the clinical progress and the cellular proliferation index Ki-67.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Granular Cell Tumor / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. S100 Proteins / analysis. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925675.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


93. Fleischhacker M, Schmidt B: Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients? Cancer Biomark; 2010;6(3-4):211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?
  • Recent results indicate that not only intact circulating tumor cells but also extracellular, free-circulating nucleic acids containing tumor-associated genetic alterations can be detected in peripheral blood of cancer patients.
  • The development of sensitive and specific methods for the detection of miniscule quantities of DNA or RNA has made it possible to isolate and characterize these tumor-associated alterations in cell-free circulating nucleic acids.
  • So far almost all genetic alterations found in a tumor were also found in free-circulating nucleic acids, i.e. point mutations (like in p53, K-ras, myc, EGFR, etc.
  • ), microsatellite alterations, epigenetic alterations like hypermethylation of CpG islands in promotor regions and the overexpression of tumor-associated genes at the mRNA and the microRNA level.
  • In this review we discuss the potential use of the detection and characterization of tumor-associated alterations in free-circulating nucleic acids for the differentiation between patients with benign lung diseases and lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / genetics. Lung Neoplasms / blood. Lung Neoplasms / genetics. Nucleic Acids / blood
  • [MeSH-minor] DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Humans


94. D'Agostini F, Mastracci L, Izzotti A, Balansky R, Pennisi TM, Steele VE, De Flora S: Modulation by phenethyl isothiocyanate and budesonide of molecular and histopathologic alterations induced by environmental cigarette smoke in mice. Cancer Prev Res (Phila); 2009 Jun;2(6):546-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our discovery that the perinatal period involves nucleotide modifications and gene overexpression in mouse lung prompted us to evaluate whether mice may become more susceptible to cigarette smoke when exposure starts immediately after birth.
  • However, after 4 months of exposure to ECS followed by 7 months of recovery in filtered air, the lung tumor yield was rather low.
  • After weanling, the mice exposed to ECS since birth underwent a variety of alterations of molecular and cytogenetical end points, and 11 months after birth, they exhibited significant histopathologic changes, such as pulmonary anthracosis, emphysema, hemorrhagic areas, alveolar bronchiolarization, bronchial hyperplasia, and tumors, both benign and malignant.
  • Both phenethyl isothiocyanate and budesonide, administered daily with the diet after weanling, attenuated several alterations of ECS-related biomarkers and moderately protected the lungs from histopathologic alterations, including tumors.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Budesonide / therapeutic use. Isothiocyanates / therapeutic use. Lung Neoplasms / prevention & control. Tobacco Smoke Pollution / adverse effects
  • [MeSH-minor] Adenoma / etiology. Adenoma / prevention & control. Age Factors. Animals. Animals, Newborn. Apoptosis / drug effects. Bone Marrow Cells / drug effects. Bone Marrow Cells / pathology. Carcinoma / etiology. Carcinoma / prevention & control. DNA Adducts / analysis. Drug Screening Assays, Antitumor. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Lung / chemistry. Lung / drug effects. Lung Diseases / drug therapy. Lung Diseases / pathology. Male. Mice. Precancerous Conditions / drug therapy. Precancerous Conditions / pathology. Pregnancy. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19491290.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / DNA Adducts; 0 / Isothiocyanates; 0 / Tobacco Smoke Pollution; 51333-22-3 / Budesonide; 6U7TFK75KV / phenethyl isothiocyanate
  •  go-up   go-down


95. Juhász C, Muzik O, Lu X, Jahania MS, Soubani AO, Khalaf M, Peng F, Mangner TJ, Chakraborty PK, Chugani DC: Quantification of tryptophan transport and metabolism in lung tumors using PET. J Nucl Med; 2009 Mar;50(3):356-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of tryptophan transport and metabolism in lung tumors using PET.
  • Abnormal tryptophan metabolism catalyzed by indoleamine 2,3-dioxygenase may play a prominent role in tumor immunoresistance in many tumor types, including lung tumors.
  • The goal of this study was to evaluate the in vivo kinetics of alpha-(11)C-methyl-l-tryptophan (AMT), a PET tracer for tryptophan metabolism, in human lung tumors.
  • The kinetic values were compared between tumors and unaffected lung tissue, tested against a simplified analytic approach requiring no arterial blood sampling, and correlated with standardized uptake values (SUVs) obtained from (18)F-FDG PET/CT scans.
  • RESULTS: Most non-small cell lung cancers (NSCLCs) showed prolonged retention of AMT, but 3 other lesions (2 benign lesions and a rectal cancer metastasis) and unaffected lung tissue showed no such retention.
  • Transport and metabolic rates of AMT were substantially higher in NSCLCs than in the other tumors and unaffected lung tissue.
  • A simplified analytic approach provided an excellent estimate of transport rates but only suboptimal approximation of tryptophan metabolic rates. (18)F-FDG SUVs showed a positive correlation with AMT uptake, suggesting higher tryptophan transport and metabolism in tumors with higher proliferation rates.
  • CONCLUSION: Prolonged retention of AMT in NSCLCs suggests high metabolic rates of tryptophan in these tumors.
  • AMT PET/CT may be a clinically useful molecular imaging method for personalized cancer treatment by identifying and monitoring patients who have increased tumor tryptophan metabolism and are potentially sensitive to immunopharmacotherapy with indoleamine 2,3-dioxygenase inhibitors.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 2001 Oct 1;1514(2):291-302 [11557028.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3837-44 [11051227.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):151-5 [12209992.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Oct;303(1):1-10 [12235226.001]
  • [Cites] Pflugers Arch. 2003 Feb;445(5):529-33 [12634921.001]
  • [Cites] Nat Med. 2003 Oct;9(10):1269-74 [14502282.001]
  • [Cites] Trends Mol Med. 2004 Jan;10(1):15-8 [14720581.001]
  • [Cites] Biochim Biophys Acta. 2004 Feb 10;1661(1):106-12 [14967480.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):74-84 [15068672.001]
  • [Cites] J Biol Chem. 1978 Jul 10;253(13):4700-6 [26687.001]
  • [Cites] J Cereb Blood Flow Metab. 1983 Mar;3(1):1-7 [6822610.001]
  • [Cites] J Nucl Med. 1986 Feb;27(2):235-8 [3712040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Feb;85(4):1242-6 [3124115.001]
  • [Cites] Adv Exp Med Biol. 1991;294:345-58 [1772073.001]
  • [Cites] J Nucl Med. 1995 Jul;36(7):1249-54 [7790951.001]
  • [Cites] Nucl Med Biol. 1996 Nov;23(8):1005-8 [9004289.001]
  • [Cites] Synapse. 1998 Jan;28(1):33-43 [9414016.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23629-32 [9726963.001]
  • [Cites] Immunol Today. 1999 Oct;20(10):469-73 [10500295.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):390-6 [15967116.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):6030-9 [16115948.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1144-51 [16489067.001]
  • [Cites] J Cereb Blood Flow Metab. 2006 Mar;26(3):345-57 [16079785.001]
  • [Cites] Curr Opin Pharmacol. 2006 Aug;6(4):350-4 [16690355.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1610-6 [17530250.001]
  • [Cites] PLoS Biol. 2007 Oct;5(10):e257 [17896864.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1258-62 [17700060.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):742-8 [18253116.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2310-7 [18413819.001]
  • [Cites] J Physiol. 2001 Mar 1;531(Pt 2):417-23 [11230514.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Jan;20(1):2-9 [10616786.001]
  • [Cites] Neurochem Int. 2002 Jun;40(7):603-10 [11900855.001]
  • (PMID = 19223408.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123451-01A2; United States / NCI NIH HHS / CA / R01 CA123451-02; United States / NCI NIH HHS / CA / R01 CA123451; United States / NCI NIH HHS / CA / CA-12341; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 13510-08-2 / alpha-methyltryptophan; 8DUH1N11BX / Tryptophan
  • [Other-IDs] NLM/ NIHMS148209; NLM/ PMC2784997
  •  go-up   go-down


96. Wen SL, Zhou X, Hu HH, Peng ZZ: [Clinical characteristics of 8 cases of primary tracheal tumors]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Sep;32(9):660-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of 8 cases of primary tracheal tumors].
  • OBJECTIVE: To explore the clinical characteristics of primary tracheal tumors and therefore to improve the diagnosis and treatment.
  • METHODS: A retrospective analysis of the clinical data of 8 patients with primary tracheal tumors admitted to our department during the period of May 1994 to May 2006 was performed, with detailed description of the clinical manifestations, chest radiography, fiberoptic bronchoscopy, lung function measurements, treatment and prognosis for 4 cases.
  • Examination by fiberoptic bronchoscopy confirmed the diagnosis of tracheal tumor in all the cases.
  • One case with benign neurinoma and 2 cases with adenoid cystic carcinomas had a long-term postoperative remission.
  • CONCLUSIONS: Primary tracheal tumors occur infrequently and early clinical symptoms are unspecific.
  • Early diagnosis can be made by chest CT and fiberoptic bronchoscopy.
  • Benign tracheal tumors can be resected, and for some low-grade malignant tumors surgical resection and postoperative radiotherapy can improve long term survival.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / therapy. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079278.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Matyakhina L, Bei TA, McWhinney SR, Pasini B, Cameron S, Gunawan B, Stergiopoulos SG, Boikos S, Muchow M, Dutra A, Pak E, Campo E, Cid MC, Gomez F, Gaillard RC, Assie G, Füzesi L, Baysal BE, Eng C, Carney JA, Stratakis CA: Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab; 2007 Aug;92(8):2938-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors.
  • CONTEXT: Carney triad (CT) describes the association of paragangliomas (PGLs) with gastrointestinal stromal tumors (GISTs) and pulmonary chondromas.
  • OBJECTIVE: Our objective was to investigate the possibility that patients with CT and/or their tumors may harbor mutations of the SDHB, SDHC, SDHD, KIT, and PDGFRA genes and identify any other genetic alterations in CT tumors.
  • We sequenced the stated genes and performed comparative genomic hybridization on a total of 41 tumors.
  • Comparative genomic hybridization revealed a number of DNA copy number changes: losses dominated among benign lesions, there were an equal number of gains and losses in malignant lesions, and the average number of alterations in malignant tumors was higher compared with benign lesions.
  • GISTs and PGLs in CT are associated with chromosome 1 and other changes that appear to participate in tumor progression and point to their common genetic cause.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Gastrointestinal Neoplasms / genetics. Gastrointestinal Stromal Tumors / genetics. Germ-Line Mutation / genetics. Lung Neoplasms / genetics. Paraganglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. DNA, Neoplasm / genetics. Female. Gene Dosage. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Male. Nucleic Acid Hybridization. Retrospective Studies. Succinate Dehydrogenase / genetics. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Genetic Alliance. consumer health - Paragangliomas 1.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535989.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.3.99.1 / Succinate Dehydrogenase
  •  go-up   go-down


98. Rodríguez PM, Freixinet JL, Plaza ML, Camacho R: Unusual primary pleural leiomyoma. Interact Cardiovasc Thorac Surg; 2010 Mar;10(3):441-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A computed tomography confirmed the existence of a solid right pleural tumor which had compressed and displaced the lung, mediastinum and heart.
  • Surgical excision was done and the tumor was not associated to vascular, broncho-pulmonary or mediastinal structures.
  • The definitive diagnosis was primary pleural leiomyoma.
  • Primary pleural leiomyoma should be included in a differential diagnosis of pleural tumors and suspected in asymptomatic patients with radiologically-apparent benign tumors and the presence of smooth muscle fibers in the biopsy.
  • [MeSH-major] Leiomyoma / diagnosis. Pleural Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040476.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Okoromah CN, Adegbola TA, Ojuola OI: Neurofibromatosis with malignant transformation presenting as an emergency in a nigerian child: a case report. Niger Postgrad Med J; 2005 Mar;12(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis is a rare disease, and malignant transformation of this otherwise benign tumor is extremely rare in childhood.
  • [MeSH-minor] Cerebellar Neoplasms / secondary. Child. Fatal Outcome. Female. Humans. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Mediastinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827598.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Number-of-references] 15
  •  go-up   go-down


100. Shimizu K, Okita R, Hamai Y: [Intrabronchial leiomyoma treated with endoscopic resection; report of a case]. Kyobu Geka; 2008 Feb;61(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serial chest computed tomography (CT) showed ground-glass attenuation, which measured 2 cm on S1+2 of the left lung.
  • When bronchofiberscopy was performed to make a diagnosis, a tumor with a smooth surface was revealed which obstructed the right middle bronchus.
  • At first, a wide wedge resection of left lung tumor was performed.
  • Secondly, a bronchus tumor was successively removed using a high frequency snare and a laser by a bronchofiberscopy.
  • Leiomyoma of the bronchus is rare benign tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268959.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement